J. Beijnen

发表

Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab

C. Damen, Weibin Chen, A. Chakraborty, 2009, Journal of the American Society for Mass Spectrometry.

Characterization of the MRP4- and MRP5-mediated Transport of Cyclic Nucleotides from Intact Cells*

J. Wijnholds, J. Beijnen, P. Wielinga, 2003, The Journal of Biological Chemistry.

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.

J. Wanders, E. Raymond, J. Schellens, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

J. Wanders, J. Beijnen, G. Milano, 2008, British Journal of Cancer.

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood

J. Beijnen, M. Ravic, J. Schellens, 2003, Anti-cancer drugs.

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2002, Anti-cancer drugs.

E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.

J. Schellens, J. Beijnen, C. van Kesteren, 2002, Anti-cancer drugs.

The G2 checkpoint—a node‐based molecular switch

J. Beijnen, T. Würdinger, M. D. de Gooijer, 2017, FEBS open bio.

Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Gait dynamics to optimize fall risk assessment in geriatric patients admitted to an outpatient diagnostic clinic

T. Hortobágyi, N. Vuillerme, C. Lamoth, 2017, PloS one.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2017, Cancer Chemotherapy and Pharmacology.

Extensive Metabolism and Hepatic Accumulation of Gemcitabine After Multiple Oral and Intravenous Administration in Mice

J. Schellens, J. Beijnen, D. Pluim, 2008, Drug Metabolism and Disposition.

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry

J. Schellens, J. Beijnen, R. C. Garner, 2007, Investigational New Drugs.

Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles

J. Schellens, J. Beijnen, P. Borst, 2004, Cancer Research.

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria

H. Rosing, J. Beijnen, F. Kuipers, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk

H. Rosing, J. Beijnen, A. V. van Herwaarden, 2006, Molecular and Cellular Biology.

The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel

J. Schellens, H. Rosing, J. Beijnen, 2013, Clinical Pharmacokinetics.

Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.

H. Rosing, J. Beijnen, H. Guchelaar, 2013, Clinical therapeutics.

DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A.

A. V. van Kuilenburg, H. Rosing, J. Beijnen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Drug interactions in oncology.

J. Schellens, J. Beijnen, 2004, The Lancet. Oncology.

Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?

H. Rosing, J. Beijnen, E. Stokvis, 2005, Rapid communications in mass spectrometry : RCM.

Abstract 5687: Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer

J. Beijnen, W. Boogerd, P. Gaillard, 2012 .

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.

A. Paci, J. Beijnen, Nicolas Widmer, 2014, European journal of cancer.

A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal

J. Beijnen, P. D. de Vries, T. Dorlo, 2012, PLoS neglected tropical diseases.

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation

J. Beijnen, T. Dorlo, Semra Palić, 2019, Antimicrobial Agents and Chemotherapy.

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study

J. Beijnen, A. Hailu, T. Dorlo, 2020, The Journal of antimicrobial chemotherapy.

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

J. Beijnen, S. Rijal, M. Vanaerschot, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

E. Khalil, J. Beijnen, M. Karlsson, 2017, The Journal of antimicrobial chemotherapy.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis

J. Schellens, J. Beijnen, T. Dorlo, 2018, Front. Cell. Infect. Microbiol..

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

A. V. van Kuilenburg, J. Schellens, H. Rosing, 2018, The Lancet. Oncology.

Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review.

J. Schellens, H. Rosing, J. Beijnen, 2014, Bioanalysis.

Naked Plasmid DNA Formulation: Effect of Different Disaccharides on Stability after Lyophilisation

J. Beijnen, J. Haanen, S. Quaak, 2010, AAPS PharmSciTech.

Application of PET/CT in the development of novel anticancer drugs.

J. Schellens, J. Beijnen, D. Boss, 2008, The oncologist.

ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation

J. Beijnen, M. Valk, A. Schinkel, 2019, Archives of Toxicology.

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

J. Schellens, J. Beijnen, J. Schellens, 2000, Journal of the National Cancer Institute.

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2003, Cancer research.

Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone

Jos H Beijnen, J. Beijnen, A. Schinkel, 2009, Drug Metabolism and Disposition.

Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma.

J. Schellens, J. Beijnen, J. S. Lagas, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.

J. Schellens, J. Beijnen, I. Meijerman, 2007, Cancer treatment reviews.

Cytostatic drugs in infants: a review on pharmacokinetic data in infants.

J. Beijnen, J. N. van den Anker, H. van den Berg, 2012, Cancer treatment reviews.

Clinical Pharmacokinetics of Cyclophosphamide

S. Rodenhuis, J. Beijnen, A. Huitema, 1979, Clinical pharmacokinetics.

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Cancer Chemotherapy and Pharmacology.

MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4

J. Schellens, J. Beijnen, A. V. van Herwaarden, 2005, Drug Metabolism and Disposition.

Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.

J. Schellens, J. Beijnen, A. Huitema, 2006, Basic & clinical pharmacology & toxicology.

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)

M. Lamfers, J. Beijnen, A. Kuin, 1999, British Journal of Cancer.

Limited-sampling models for anticancer agents

J. H. Beijnen, J. Beijnen, R. Maes, 2005, Journal of Cancer Research and Clinical Oncology.

Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology

J. Schellens, J. Beijnen, C. van Kesteren, 2003, Investigational New Drugs.

Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.

J. Beijnen, L. Schaaf, O. van Tellingen, 1998, Cancer research.

Limited sampling models for topotecan pharmacokinetics.

J. Verweij, H. Rosing, J. Beijnen, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan

Jos H Beijnen, J. Beijnen, Jin Zhao, 2007, Clinical Cancer Research.

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

J. Schellens, J. Beijnen, P. Breedveld, 2006, Trends in pharmacological sciences.

Blood–brain barrier and chemotherapeutic treatment of brain tumors

J. Beijnen, O. van Tellingen, W. Boogerd, 2006, Expert review of neurotherapeutics.

Detection of Single Nucleotide Polymorphisms in theABCG2Gene in a Dutch Population

J. Schellens, J. Beijnen, B. Koeleman, 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study

J. Schellens, J. Beijnen, R. Mathijssen, 2019, Pharmaceutical Research.

P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib

H. Rosing, J. Beijnen, M. Tibben, 2020, International journal of cancer.

Hepatotoxicity and metabolism of trabectedin: a literature review.

J. Schellens, J. Beijnen, J. Beumer, 2005, Pharmacological research.

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

J. Schellens, J. Beijnen, C. van Kesteren, 2003, Anti-cancer drugs.

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

M. Hidalgo, G. Weiss, H. Rosing, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

J. Schellens, H. Rosing, J. Beijnen, 2002, Anti-cancer drugs.

Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.

H. Rosing, J. Beijnen, M. Hillebrand, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

H. Rosing, J. Beijnen, M. Hillebrand, 1998, Journal of mass spectrometry : JMS.

Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.

Marie-Christine W. Gast, Jos H Beijnen, Marie-Christine W Gast, 2006, Trends in pharmacological sciences.

Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model.

J. Beijnen, R. Devlieger, F. Amant, 2010, Gynecologic oncology.

P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

J. Beijnen, A. Schinkel, S. Durmuş, 2013, Pharmacological research.

A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute

J. Beijnen, K. Heinhuis, Hannerieke J. Barkman, 2020, International Journal of Clinical Pharmacy.

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

S. Linn, J. Schellens, J. Beijnen, 2013, BMC Cancer.

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

J. Wanders, E. Raymond, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Jos H. Beijnen, Ron J. Keizer, Alwin D. R. Huitema, 2010, Clinical pharmacokinetics.

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

Ji-Ying Song, Jos H Beijnen, H. Rosing, 2007, The Journal of clinical investigation.

PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

J. Schellens, J. Beijnen, I. Meijerman, 2009, Cancer Chemotherapy and Pharmacology.

Treatment of hypertension in an elderly outpatient population in the Netherlands.

J. Beijnen, J. V. van Campen, M. R. Mac Gillavry, 2009, The American journal of geriatric pharmacotherapy.

A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.

J. Baars, J. Beijnen, A. Huitema, 2009, Cancer biotherapy & radiopharmaceuticals.

Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study

F. van Leth, J. Beijnen, T. Macgregor, 2005, Antiviral therapy.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

J. Wanders, C. Punt, E. Raymond, 2005, Investigational New Drugs.

Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals

J. Beijnen, A. Huitema, J. Prins, 2005, Clinical pharmacokinetics.

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

J. Schellens, J. Beijnen, O. van Tellingen, 2002, Cancer research.

CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity

J. Schellens, J. Beijnen, A. Zandvliet, 2007, Clinical Cancer Research.

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

J. Schellens, J. Beijnen, A. Huitema, 2017, Clinical pharmacology and therapeutics.

Clinical pharmacology of carboplatin administered in combination with paclitaxel.

G. Giaccone, P. Postmus, J. Beijnen, 1997, Seminars in oncology.

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

G. Giaccone, O. Dalesio, P. Postmus, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

A. C. Dubbelman, J. Beijnen, W. W. ten Bokkel Huinink, 1997, British Journal of Cancer.

Symptoms and treatment in cancer therapy-induced early menopause.

J. Schellens, J. Beijnen, A. Boekhout, 2006, The oncologist.

Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices.

A. C. Dubbelman, J. Schellens, H. Rosing, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

J. Schellens, H. Rosing, J. Beijnen, 2008, Clinical Cancer Research.

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)

A. Jager, J. Bono, J. Schellens, 2019, Investigational New Drugs.

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.

J. Beijnen, A. Hsu, J. Lange, 1999, AIDS.

leishmaniasis: a systematic review

J. Beijnen, M. Balasegaram, A. Kip, 2014 .

From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of clinical pharmacology.

Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

J. Wanders, J. Schellens, J. Beijnen, 2011, The AAPS Journal.

PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression

J. Schellens, J. Beijnen, G. Milano, 2008, Clinical pharmacology and therapeutics.

The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers

J. Schellens, J. Beijnen, A. Goey, 2013, European Journal of Clinical Pharmacology.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

J. Wanders, J. Schellens, J. Beijnen, 2013, British journal of clinical pharmacology.

Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology

J. Schellens, J. Beijnen, A. Zandvliet, 2008, Clinical pharmacokinetics.

Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors

D. Mould, J. Schellens, H. Rosing, 2002, Clinical pharmacology and therapeutics.

Adult outpatient experience of the 2009 H1N1 pandemic: Clinical course, pathogens, and evaluation of case definitions

J. Beijnen, E. V. van Gorp, J. Mulder, 2011, Journal of Infection.

Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam

J. Beijnen, A. V. van Herwaarden, A. Schinkel, 2009, Drug Metabolism and Disposition.

Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam

J. Beijnen, A. Schinkel, R. Sparidans, 2009 .

Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk

L. Wessels, J. Schellens, J. Beijnen, 2008, Biomarker insights.

Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut

J. Schellens, J. Beijnen, O. van Tellingen, 2002, Cancer Chemotherapy and Pharmacology.

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2001, British Journal of Cancer.

Etoposide phosphate, the water soluble prodrug of etoposide

J. Beijnen, A. H. I. Witterland, C. Koks, 1996, Pharmacy World and Science.

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

J. Beijnen, P. Borst, A. Sparreboom, 1997, British Journal of Cancer.

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 2001, European Journal of Clinical Pharmacology.

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)

J. Schellens, H. Rosing, J. Beijnen, 2004, Cancer Chemotherapy and Pharmacology.

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

J. Schellens, J. Beijnen, O. van Tellingen, 2004, Investigational New Drugs.

Survival after massive ecstasy overdose.

J. Beijnen, R. Maes, P. Meenhorst, 1998, Journal of toxicology. Clinical toxicology.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and 11C-Erlotinib PET

A. Lammertsma, M. Yaqub, J. Schellens, 2017, The Journal of Nuclear Medicine.

The impact of P‐glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2018, International journal of cancer.

Complement activation by PEGylated liposomes containing prednisolone.

J. Beijnen, G. Storm, J. Szebeni, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Review on the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and its phase I and phase II metabolites in biological matrices, foodstuff and beverages.

J. Schellens, H. Rosing, J. Beijnen, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action

J. Beijnen, Ellen J B Derissen, 2020, Clinical Pharmacokinetics.

In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug

J. Schellens, J. Beijnen, E. Brandon, 2004, Investigational New Drugs.

Model‐Based Evaluation of Similarity in Pharmacokinetics of Two Formulations of the Blood‐Derived Plasma Product C1 Esterase Inhibitor

J. Beijnen, A. Huitema, R. Keizer, 2012, Journal of clinical pharmacology.

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar

J. Schellens, J. Beijnen, A. Huitema, 2017, Drug Delivery and Translational Research.

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar☆

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of pharmaceutical analysis.

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

J. Beijnen, A. Schinkel, O. Tellingen, 1999, British Journal of Cancer.

Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export

J. Lankelma, R. Evers, J. Beijnen, 2000, British Journal of Cancer.

Aspects of the degradation kinetics of doxorubicin in aqueous solution

J. Beijnen, O. V. D. Houwen, W. Underberg, 1986 .

Chemical stability of n trifluoroacetyldoxorubicin 14 valerate ad 32 in aqueous media and after liposome encapsulation

J. Beijnen, G. Storm, A. Bult, 1989 .

Aspects of the chemical stability of doxorubicin and seven other anthracydines in acidic solution

J. Beijnen, W. Underberg, G. Wiese, 1985, Pharmaceutisch Weekblad.

Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays.

J. Schellens, H. Rosing, J. Beijnen, 2014, Bioanalysis.

Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring

J. Schellens, J. Beijnen, U. Jaehde, 2012, Clinical Pharmacokinetics.

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

H. Hollema, A. Boddy, D. Richel, 2007, Clinical Cancer Research.

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

J. Schellens, H. Rosing, J. Beijnen, 2007, British journal of clinical pharmacology.

Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors

J. Schellens, J. Beijnen, A. Huitema, 2006, Clinical Cancer Research.

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

S. Rodenhuis, J. Schellens, J. Beijnen, 2005, British journal of clinical pharmacology.

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2004, Analytical biochemistry.

Integrated Population Pharmacokinetic Model of Both Cyclophosphamide and Thiotepa Suggesting a Mutual Drug–Drug Interaction

S. Rodenhuis, J. Beijnen, A. Huitema, 2004, Journal of Pharmacokinetics and Pharmacodynamics.

A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).

A. Harris, L. Aarons, J. Schellens, 2003, British journal of clinical pharmacology.

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

J. Verweij, J. Beijnen, A. Sparreboom, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

J. Schellens, J. Beijnen, J. Schellens, 1999, British Journal of Cancer.

High-performance liquid chromatographic analysis of the antitumour drug camptothecin and its lactone ring-opened form in rat plasma.

H. Rosing, J. Beijnen, W. W. ten Bokkel Huinink, 1993, Journal of chromatography.

The Pharmacokinetics of Topotecan and Its Carboxylate Form Following Separate Intravenous Administration to the Dog

H. Rosing, J. Beijnen, B. Davies, 1997, Pharmaceutical Research.

Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review

J. Beijnen, A. Bult, J. D. Vries, 1996 .

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug

J. Schellens, J. Beijnen, E. Brandon, 2006, Investigational New Drugs.

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

J. Schellens, J. Beijnen, E. Brandon, 2005, Anti-cancer drugs.

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

J. Schellens, J. Beijnen, G. Sanderink, 2005, Cancer Chemotherapy and Pharmacology.

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

J. Schellens, J. Beijnen, C. M. Kruijtzer, 2002, The oncologist.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Degradation kinetics of gonadorelin in aqueous solution.

J. Beijnen, A. Bult, W. Underberg, 1996, Journal of pharmaceutical sciences.

The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry.

C. Damen, J. Schellens, H. Rosing, 2009, Analytical biochemistry.

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

J. Schellens, J. Beijnen, M. Deenen, 2013, Therapeutic advances in medical oncology.

Limited sampling model for area under the concentration time curve of total topotecan.

M. Ratain, J. Verweij, J. Beijnen, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Development and Validation of Limited-Sampling Models for the Antiretroviral Agent Zidovudine

H. Rosing, J. Beijnen, A. Bult, 1993 .

Chloroquine Administration in Breastfeeding Mothers Associates with Increased HIV-1 Plasma Viral Loads

W. Paxton, J. Beijnen, F. Wit, 2020 .

The functional role of P-glycoprotein in the blood-brain barrier.

J. Beijnen, O. van Tellingen, O. Tellingen, 1997, Journal of pharmaceutical sciences.

Toxicological analysis of azide and cyanide for azide intoxications using gas chromatography

D. D. de Lange, H. Rosing, J. Beijnen, 2020, Basic & clinical pharmacology & toxicology.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

P. Reiss, J. Beijnen, F. Wit, 2000, AIDS.

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

J. Montaner, D. Cooper, P. Reiss, 2001, AIDS.

Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population

J. Dieleman, J. Beijnen, A. Huitema, 2003, Clinical pharmacokinetics.

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.

A. Jager, J. Beijnen, R. Mathijssen, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

W. Zwart, L. Natarajan, J. Pierce, 2017, Breast Cancer Research and Treatment.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen

W. Zwart, S. Linn, J. Beijnen, 2015, Clinical Pharmacokinetics.

DNA-based drug interactions of cisplatin.

J. Schellens, J. Beijnen, R. V. van Waardenburg, 2002, Cancer treatment reviews.

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel–cisplatin–topotecan in a phase I study

J. Schellens, J. Beijnen, D. Pluim, 2002, Anti-cancer drugs.

Concise drug review: pazopanib and axitinib.

J. Schellens, J. Beijnen, R. van Geel, 2012, The oncologist.

O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.

H. Rosing, J. Beijnen, A. Bult, 1998, Anti-cancer drugs.

Transposon leads to contamination of clinical pDNA vaccine.

T. Schumacher, J. Beijnen, J. Haanen, 2013, Vaccine.

Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant?

T. Schumacher, J. Beijnen, W. Hennink, 2010, International journal of pharmaceutics.

Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.

J. Beijnen, J. Haanen, S. Quaak, 2009, Journal of pharmaceutical and biomedical analysis.

The domain architecture of the protozoan protein J-DNA–binding protein 1 suggests synergy between base J DNA binding and thymidine hydroxylase activity

Wouter G. Touw, J. Beijnen, I. Phan, 2019, The Journal of Biological Chemistry.

The domain architecture of JBP1 suggests synergy between J-base DNA binding and thymidine hydroxylase activity

Wouter G. Touw, J. Beijnen, I. Phan, 2018 .

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid

J. Beijnen, O. van Tellingen, A. Schinkel, 2005, International journal of cancer.

Taxanes: a new class of antitumor agents.

J. Beijnen, W. W. ten Bokkel Huinink, H. Pinedo, 1995, Cancer investigation.

Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.

J. Beijnen, A. Sparreboom, O. van Tellingen, 1995, Journal of chromatography. B, Biomedical applications.

Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel

J. Beijnen, J. Vermorken, M. Huizing, 1997 .

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

J. Beijnen, P. Borst, A. Sparreboom, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

Der, J. Beijnen, O. van Tellingen, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography

J. Beijnen, O. Tellingen, W. Nooijen, 1993, Investigational New Drugs.

Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography

J. Beijnen, O. Tellingen, W. Nooijen, 2004, Cancer Chemotherapy and Pharmacology.

Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.

J. Beijnen, O. van Tellingen, W. Nooijen, 1993, Cancer research.

Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors

A. C. Dubbelman, J. Schellens, J. Beijnen, 2012, Cancer Chemotherapy and Pharmacology.

Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.

J. Schellens, J. Beijnen, M. Vlaming, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices.

H. Rosing, J. Beijnen, A. Huitema, 2020, Bioanalysis.

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

S. Linn, H. Rosing, J. Beijnen, 2020, European Journal of Clinical Pharmacology.

Clinical Relevance: Drug–Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity

J. Schellens, J. Beijnen, R. Mazzanti, 2006 .

Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology

H. Rosing, J. Beijnen, J. Roosendaal, 2020, Drugs in R&D.

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology

H. Rosing, J. Beijnen, J. Roosendaal, 2020, Clinical pharmacology in drug development.

p53 selected as molecule of the year 1993

J. Beijnen, 1994, Pharmacy World and Science.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure–response relationships

J. Schellens, J. Beijnen, N. Saravia, 2018, Journal of Antimicrobial Chemotherapy.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′‐difluorodeoxyuridine and their nucleotides

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.

H. Rosing, J. Beijnen, R. ter Heine, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

J. Beijnen, A. Huitema, E. V. van Gorp, 2010, British journal of clinical pharmacology.

Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).

G. Giaccone, J. Beijnen, W. W. ten Bokkel Huinink, 1994, Seminars in oncology.

Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?

F. van Leth, J. Beijnen, T. Macgregor, 2005, Antiviral therapy.

Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment

J. Beijnen, E. V. van Gorp, R. ter Heine, 2003, AIDS.

Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD‐1 Expression Levels and PD‐1 Receptor Occupancy by Nivolumab and Pembrolizumab

J. Schellens, J. Beijnen, D. Pluim, 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

J. Baars, J. Beijnen, A. Huitema, 2010, Human antibodies.

Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces.

K. Wirtz, T. van der Poll, J. Wijnholds, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor-Mediated CYP3A4 Induction

J. Schellens, J. Beijnen, I. Meijerman, 2008, Drug Metabolism and Disposition.

Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours

J. Beijnen, A. Bergman, B. van Triest, 2021, Cancer Chemotherapy and Pharmacology.

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Pharmacogenetics and genomics.

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2007, Cancer Chemotherapy and Pharmacology.

SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES

J. Schellens, J. Beijnen, A. Zandvliet, 2006, Drug Metabolism and Disposition.

Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

J. Schellens, J. Beijnen, H. D. van den Bongard, 2004, Investigational New Drugs.

The use of the Calvert formula to determine the optimal carboplatin dosage

S. Rodenhuis, J. Beijnen, R. Maes, 2005, Journal of Cancer Research and Clinical Oncology.

Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and response.

A. C. Dubbelman, J. Beijnen, J. Mcvie, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

A. Wafelman, J. Beijnen, C. Hoefnagel, 1994, European Journal of Nuclear Medicine.

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

J. Schellens, J. Beijnen, D. Pluim, 2003, Biochemical pharmacology.

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

H. Rosing, J. Beijnen, J. Lieverst, 2002, British Journal of Cancer.

Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.

J. Schellens, J. Beijnen, R. Sparidans, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.

J. Beijnen, A. Huitema, E. V. van Gorp, 2005, British journal of clinical pharmacology.

Protein kinase C as a target for new anti-cancer agents

J. Beijnen, A. Bult, R. van Gijn, 1999 .

Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes

J. Goldstein, J. Beijnen, A. V. van Herwaarden, 2008, Molecular Pharmacology.

Degradation kinetics of aplidine, a new marine antitumoural cyclic peptide, in aqueous solution.

J. Beijnen, H. Lingeman, A. Bult, 2001, Journal of chromatography. B, Biomedical sciences and applications.

P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2013, International journal of cancer.

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

J. Schellens, J. Beijnen, P. Baas, 2011, Lung cancer.

Breast cancer in pregnancy: recommendations of an international consensus meeting.

L. Lagae, P. Neven, R. Rouzier, 2010, European journal of cancer.

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

J. Beijnen, A. Schinkel, S. Durmuş, 2012, Molecular pharmaceutics.

Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples

J. Schellens, J. Beijnen, O. van Tellingen, 2003, Laboratory animals.

Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing.

H. Rosing, J. Beijnen, P. L. Jacobs, 2013, Bioanalysis.

Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

J. Schellens, J. Beijnen, D. Pluim, 2004, Clinical Cancer Research.

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose

H. Rosing, J. Beijnen, A. Huitema, 2020, European Journal of Clinical Pharmacology.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2017, Cancer Chemotherapy and Pharmacology.

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

J. Schellens, J. Beijnen, E. Voest, 2011, Cancer treatment reviews.

Strategies to target drugs to gliomas and CNS metastases of solid tumors

J. Schellens, J. Beijnen, A. Huitema, 2016, Journal of Neurology.

Paclitaxel (Taxol) concentrations in brain tumor tissue.

M. Taphoorn, J. Heimans, J. Beijnen, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.

E. Westerhout, Mohamed Hamdi, J. Schellens, 2015, Journal of pharmaceutical and biomedical analysis.

ADME‐Enabling Technologies in Drug Design and Development. Edited by Donglu Zhang and Sekhar Surapaneni

Jos H. Beijnen, J. Beijnen, 2013 .

Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions.

J. Beijnen, J. V. van Campen, L. Tulner, 2009, The American journal of geriatric pharmacotherapy.

Reply to T. Magnes et al.

J. Schellens, J. Beijnen, J. Severens, 2016, Journal of Clinical Oncology.

Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors

D. Richel, J. Schellens, J. Beijnen, 2007, Clinical Cancer Research.

Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

J. Schellens, J. Beijnen, I. E. Kuppens, 2004, Clinical colorectal cancer.

Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.

H. Rosing, J. Beijnen, M. Hillebrand, 2015, International journal of pharmaceutics.

Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors

J. Schellens, J. Beijnen, E. van de Steeg, 2009, Drug Metabolism and Disposition.

Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors

J. Schellens, J. Beijnen, E. Voest, 2008, Clinical Cancer Research.

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

J. Schellens, J. Beijnen, J. Bonneterre, 2006, Clinical Cancer Research.

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

D. Richel, J. Beijnen, W. W. ten Bokkel Huinink, 2004, British Journal of Cancer.

High-Performance Liquid Chromatographic Analysis of the Anticancer Drug Irinotecan (CPT-11) and Its Active Metabolite SN-38 in Human Plasma

J. Schellens, H. Rosing, J. Beijnen, 2003, Therapeutic drug monitoring.

Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.

A. Ganser, J. Wanders, H. Rosing, 2002, European journal of cancer.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

A. V. van Kuilenburg, J. Schellens, H. Rosing, 2019, European journal of cancer.

Novel Clinical Trial Designs for Innovative Therapies

J. Schellens, J. Beijnen, J. Schellens, 2009, Clinical pharmacology and therapeutics.

Precision Dosing of Targeted Therapies Is Ready for Prime Time

J. Beijnen, A. Sparreboom, R. Mathijssen, 2021, Clinical Cancer Research.

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)

J. Beijnen, A. Schinkel, S. Durmuş, 2015, Pharmaceutical Research.

Genetically modified mouse models for oral drug absorption and disposition.

J. Beijnen, A. Schinkel, Seng Chuan Tang, 2013, Current opinion in pharmacology.

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

J. Schellens, J. Beijnen, E. Voest, 2007, Clinical Cancer Research.

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.

D. Richel, J. Schellens, H. Rosing, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.

J. Verweij, H. Rosing, J. Beijnen, 1996, British Journal of Cancer.

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice

J. Schellens, J. Beijnen, O. van Tellingen, 2008, Molecular Cancer Therapeutics.

Impact of ABC transporters on the disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine) and its mutagenic metabolites in vivo

H. Rosing, J. Beijnen, A. Schinkel, 2009 .

Multidrug Resistance Protein 1 Protects the Oropharyngeal Mucosal Layer and the Testicular Tubules against Drug-induced Damage

J. Wijnholds, J. Beijnen, P. Borst, 1998, The Journal of experimental medicine.

Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.

J. Beijnen, A. Schinkel, R. Sparidans, 2021, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir

J. Beijnen, A. Schinkel, E. Wagenaar, 2010, British journal of pharmacology.

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

H. Rosing, J. Beijnen, A. V. van Herwaarden, 2009, Cancer research.

Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients

W. van den Brink, J. Beijnen, A. Huitema, 2018, Journal of clinical psychopharmacology.

Severe Lactic Acidosis in a Diabetic Patient after Ethanol Abuse and Floor Cleaner Intake

J. Schellens, J. Beijnen, A. Huitema, 2014, Basic & clinical pharmacology & toxicology.

Oxidation of recombinant methionyl human granulocyte colony stimulating factor.

J. Beijnen, S. Scholten, A. Bult, 1998, Journal of pharmaceutical and biomedical analysis.

Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection.

J. Beijnen, R. Hoetelmans, R. Sparidans, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

S. Sundar, J. Beijnen, A. Huitema, 2021, Clinical Pharmacokinetics.

Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin

S. Rodenhuis, J. Beijnen, R. Mathôt, 2002, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial

J. Schellens, J. Beijnen, R. Mathijssen, 2017, Clinical Pharmacokinetics.

P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice

J. Beijnen, A. Schinkel, S. Durmuş, 2014, Clinical Cancer Research.

Cancer Therapy : Preclinical P-Glycoprotein , CYP 3 A , and Plasma Carboxylesterase Determine Brain and Blood Disposition of themTOR Inhibitor Everolimus ( A fi nitor ) in Mice

J. Beijnen, A. Schinkel, S. Durmuş, 2014 .

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS

H. Rosing, J. Beijnen, A. Huitema, 2021, Journal of Pharmaceutical and Biomedical Analysis.

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

S. Rodenhuis, J. Schellens, J. Beijnen, 2009, Cancer Chemotherapy and Pharmacology.

Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function

S. Rodenhuis, J. Schellens, J. Beijnen, 2006, Clinical Cancer Research.

Relationship between cisplatin administration and the development of ototoxicity.

J. Schellens, J. Beijnen, P. Baas, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors

G. Peters, G. Giaccone, J. Schellens, 2004, Clinical Cancer Research.

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study

A. V. van Kuilenburg, J. Maring, J. Schellens, 2022, Clinical pharmacology and therapeutics.

P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration

H. Rosing, J. Beijnen, A. Schinkel, 2011, Journal of Pharmacology and Experimental Therapeutics.

Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites.

J. Beijnen, R. Sparidans, Irene A. Retmana, 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.

H. Hansen, J. Verweij, H. Rosing, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

‘Flooding’ of the lungs and severe dyspnea in a patient with bronchoalveolar carcinoma

J. Beijnen, R. Keizer, P. Baas, 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir

J. Beijnen, A. Huitema, D. Pluim, 2021, The Pharmacogenomics Journal.

Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer

H. Rosing, J. Beijnen, A. Huitema, 2019, Prostate Cancer and Prostatic Diseases.

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

A. Jager, J. Bono, J. Schellens, 2019, Investigational New Drugs.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

J. Schellens, H. Rosing, J. Beijnen, 2019, Clinical Cancer Research.

Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer

H. Rosing, J. Beijnen, A. Bergman, 2019, Pharmacotherapy.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

J. Schellens, H. Rosing, J. Beijnen, 2017, European journal of cancer.

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

J. Schellens, J. Beijnen, A. Huitema, 2013, Gynecologic oncology.

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

J. Wanders, J. Schellens, J. Beijnen, 2013, Investigational New Drugs.

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

J. Wanders, J. Schellens, J. Beijnen, 2012, Cancer Chemotherapy and Pharmacology.

Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer.

J. Schellens, J. Beijnen, H. Helgason, 2010, Oncology letters.

Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors

J. Schellens, H. Rosing, J. Beijnen, 2010, Investigational New Drugs.

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

J. Wanders, J. Schellens, J. Beijnen, 2008, British Journal of Cancer.

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

H. Rosing, J. Beijnen, G. Groenewegen, 2004, British Journal of Cancer.

Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer.

E. D. de Vries, H. Rosing, J. Beijnen, 2002, Gynecologic oncology.

Coadministration o f C yclosporine S trongly E nhances t he Oral B ioavailability o f D ocetaxel

D. Richel, H. Rosing, J. Beijnen, 2001 .

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.

J. Schellens, H. Rosing, J. Beijnen, 1999, Pharmacological research.

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

H. Sindermann, J. Beijnen, W. W. ten Bokkel Huinink, 1999, British Journal of Cancer.

High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.

J. Heimans, J. Beijnen, T. Postma, 1995, Seminars in oncology.

Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry.

J. Schellens, J. Beijnen, H. Helgason, 2010, Oncology reports.

Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate.

A. Boddy, C. Damen, J. Beijnen, 2010, European journal of cancer.

P‐glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450‐3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib

J. Beijnen, A. Schinkel, E. Wagenaar, 2018, International journal of cancer.

Bioanalytical liquid chromatography‐tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates

J. Schellens, J. Beijnen, A. Schinkel, 2018, Journal of pharmaceutical and biomedical analysis.

Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

G. Peters, G. Giaccone, E. Smit, 2006, Cancer Chemotherapy and Pharmacology.

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

J. Schellens, J. Beijnen, P. Baas, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

F. Baas, J. Lankelma, J. Beijnen, 1995, Proceedings of the National Academy of Sciences of the United States of America.

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib

J. Beijnen, O. Tellingen, Levi C. M. Buil, 2015, Investigational New Drugs.

Search for Breast Cancer Biomarkers in Fractionated Serum Samples by Protein Profiling With SELDI‐TOF MS

R. Vermeulen, P. Peeters, J. Beijnen, 2012, Journal of clinical laboratory analysis.

Effect of Chinese herbs on CYP3A4 activity and expression in vitro.

J. Schellens, J. Beijnen, I. Meijerman, 2013, Journal of ethnopharmacology.

Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer

E. Smit, J. Beijnen, J. Burgers, 2021, Drugs.

Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?

E. Smit, J. Schellens, J. Beijnen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique.

J. Schellens, J. Beijnen, B. Nuijen, 2016, Cancer treatment reviews.

Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor

J. Schellens, J. Beijnen, T. Stephens, 2010, Cancer Chemotherapy and Pharmacology.

The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate

J. Schellens, J. Beijnen, R. Mazzanti, 2007, Cancer Chemotherapy and Pharmacology.

SELDI-TOF MS serum protein profiling predicts poor prognosis in renal cancer patients

J. Schellens, J. Beijnen, E. Voest, 2007 .

Ciprofloxacin Strongly Inhibits Clozapine Metabolism

J. Schellens, J. Beijnen, M. Söhne, 2009, Clinical Drug Investigation.

Preclinical pharmacokinetics of paclitaxel and docetaxel.

J. Beijnen, A. Sparreboom, O. van Tellingen, 1998, Anti-cancer drugs.

Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.

H. Rosing, J. Beijnen, M. Hillebrand, 2007, American journal of physiology. Cell physiology.

Saliva as an Alternative Body Fluid for Therapeutic Drug Monitoring of the Nonnucleoside Reverse Transcription Inhibitor Nevirapine

J. Beijnen, J. Lange, J. Mulder, 2001, Therapeutic drug monitoring.

Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.

J. Schellens, H. Rosing, J. Beijnen, 2019, Biomedical chromatography : BMC.

P-gp and taxanes

J. Beijnen, A. Schinkel, J. Hendrikx, 2014, Oncoscience.

Assessment of Performance of Manufacturing Procedures in a Unit for Production of Investigational Anticancer Agents, Using a Mixed Effects Analysis

J. Beijnen, B. Nuijen, A. Huitema, 2007, Pharmaceutical Research.

Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

J. Beijnen, A. Schinkel, B. Doğan-Topal, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

No pharmacokinetic drug–drug interaction between nevirapine and paclitaxel

J. Schellens, J. Beijnen, A. Huitema, 2005, Anti-cancer drugs.

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

J. Schellens, J. Beijnen, A. Huitema, 2017, Cancer Chemotherapy and Pharmacology.

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

J. Schellens, J. Beijnen, D. Pluim, 2013, Clinical Cancer Research.

Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis 1

H. Rosing, J. Beijnen, E. Voest, 2010 .

Impaired quality of life in treatment-seeking obese children of Dutch, Moroccan, Turkish and Surinamese descent

J. Beijnen, M. Diamant, M. de Wit, 2015, Public Health Nutrition.

A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.

E. D. de Vries, H. Rosing, J. Beijnen, 2005, European journal of cancer.

HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS FOR THE DETERMINATION OF A NOVEL POLYMER-BOUND PACLITAXEL DERIVATIVE AND FREE PACLITAXEL IN HUMAN PLASMA

J. Schellens, H. Rosing, J. Beijnen, 2000 .

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

D. Richel, J. Schellens, H. Rosing, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.

E. D. de Vries, J. Beijnen, W. T. van der Graaf, 1997, British Journal of Cancer.

Targeted toxins

J. Schellens, J. Beijnen, G. D. de Gast, 1999 .

Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.

H. Bartelink, H. Sindermann, J. Schellens, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.

J. Schellens, J. Beijnen, G. Wolbink, 2016, The oncologist.

Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

J. Schellens, J. Beijnen, P. Baas, 2005, Anti-cancer drugs.

Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib

J. Beijnen, A. Schinkel, E. Wagenaar, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.

J. Schellens, H. Rosing, J. Beijnen, 2010, Analytica chimica acta.

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

J. Wanders, J. Schellens, J. Beijnen, 2009, Investigational New Drugs.

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.

H. Rosing, J. Beijnen, A. Bergman, 2020, European journal of cancer.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

J. Beijnen, R. Mathijssen, A. Huitema, 2019, European Journal of Clinical Pharmacology.

Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

D. Richel, J. Schellens, J. Beijnen, 2007, Clinical pharmacokinetics.

Sparse Sampling Design for Therapeutic Drug Monitoring of Sequentially Administered Cyclophosphamide, Thiotepa, and Carboplatin (CTC)

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Therapeutic drug monitoring.

Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens

S. Rodenhuis, J. Beijnen, A. Huitema, 2000, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152.

J. Schellens, J. Beijnen, E. Voest, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Lycopene on the Insulin-Like Growth Factor (IGF) System in Premenopausal Breast Cancer Survivors and Women at High Familial Breast Cancer Risk

L. V. van't Veer, D. Voskuil, S. Verhoef, 2008, Nutrition and cancer.

Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers

J. Schellens, J. Beijnen, M. Joerger, 2006, European Journal of Clinical Pharmacology.

Overweight children with type 1 diabetes have a more favourable lipid profile than overweight non-diabetic children

M. Heymans, J. Beijnen, M. Diamant, 2011, European Journal of Pediatrics.

Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel

H. Rosing, J. Beijnen, E. van de Steeg, 2015, International journal of cancer.

Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs.

J. Schellens, H. Rosing, J. Beijnen, 2011, Mass spectrometry reviews.

Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis

J. Schellens, J. Beijnen, P. D. de Vries, 2014, Antimicrobial Agents and Chemotherapy.

Cancer Resistance Protein in Clinical Drug-Drug Interactions Methotrexate and Benzimidazoles : Potential Role for Breast Mechanism of the Pharmacokinetic Interaction between Updated

J. Schellens, J. Beijnen, P. Borst, 2004 .

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.

H. Rosing, J. Beijnen, A. Huitema, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Quality control of protein and peptide drugs : monoclonal antibodies and some biological response modifiers derived by recombinant DNA technology

J. Beijnen, O. Bekers, W. Underberg, 1993 .

The association of elevated alanine aminotransferase and the metabolic syndrome in an overweight and obese pediatric population of multi-ethnic origin

J. Beijnen, M. Diamant, R. K. Schindhelm, 2009, European Journal of Pediatrics.

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

J. H. Beijnen, O. van Tellingen, J. Beijnen, 1994, Cell.

ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2018, Molecular pharmaceutics.

Cancer Therapy : Preclinical Abcc 4 Together with Abcb 1 and Abcg 2 Form a Robust Cooperative Drug Ef fl ux System That Restricts the Brain Entry of Camptothecin Analogues

J. Schellens, J. Beijnen, D. Pluim, 2013 .

Taxanes: old drugs, new oral formulations.

J. Schellens, J. Beijnen, B. Nuijen, 2013, European journal of pharmacology.

Intravenous‐to‐Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel

J. Schellens, J. Beijnen, J. Schellens, 2010, Clinical pharmacology and therapeutics.

Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.

H. Schuitemaker, J. Beijnen, A. Huitema, 2007, AIDS research and human retroviruses.

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

J. Beijnen, M. Verheij, O. van Tellingen, 2004, European journal of cancer.

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice

J. Beijnen, W. Boogerd, E. Kemper, 2004, Cancer Chemotherapy and Pharmacology.

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo

J. Beijnen, O. van Tellingen, M. A. van der Valk, 2003, British Journal of Cancer.

The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

J. Beijnen, O. van Tellingen, J. van Asperen, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

J. Beijnen, O. van Tellingen, A. Schinkel, 1999, The Journal of pharmacology and experimental therapeutics.

Co-administration of cyclosporin enables oral therapy with paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 1998, The Lancet.

Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.

J. Beijnen, O. van Tellingen, O. Tellingen, 1998, Journal of chromatography. B, Biomedical sciences and applications.

The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue

J. Beijnen, O. van Tellingen, W. Boogerd, 1997, Cancer Chemotherapy and Pharmacology.

Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.

J. Beijnen, O. van Tellingen, Levi C. M. Buil, 2013, European journal of cancer.

Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.

J. Schellens, H. Rosing, J. Beijnen, 2004, Journal of mass spectrometry : JMS.

Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.

J. Schellens, J. Beijnen, O. van Tellingen, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)*

J. Beijnen, G. Reid, P. Borst, 2001, The Journal of Biological Chemistry.

Analytical techniques used to study the degradation of proteins and peptides: physical instability.

J. Beijnen, J. Marchal, A. Bult, 1998, Journal of pharmaceutical and biomedical analysis.

A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors.

J. Schellens, H. Rosing, J. Beijnen, 2006, Biomedical chromatography : BMC.

Development and validation of a UPLC-MS/MS method with a broad linear dynamic range for the quantification of morphine, morphine-3-glucuronide and morphine-6-glucuronide in mouse plasma and tissue homogenates.

H. Rosing, J. Beijnen, M. Hillebrand, 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds.

H. Rosing, J. Beijnen, T. Dorlo, 2020, Journal of pharmaceutical and biomedical analysis.

Methylphenidate for cerebral palsy with choreoathetosis.

J. Beijnen, W. Boogerd, 2000, Annals of internal medicine.

A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.

H. Rosing, J. Beijnen, L. Tulner, 2006, Rapid communications in mass spectrometry : RCM.

Chapter 3 Multidrug resistance protein 2 ( Mrp 2 ; Abcc 2 ) is an important determinant of paclitaxel pharmacokinetics

H. Rosing, J. Beijnen, A. Schinkel, 2009 .

Clinically relevant drug interactions with antiretroviral agents.

J. Beijnen, J. Mulder, R. Hoetelmans, 1997, Antiviral therapy.

Antiretroviral drugs and the central nervous system.

J. Beijnen, P. Portegies, J. Lange, 1998, AIDS.

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

J. Verweij, J. Schellens, H. Rosing, 1995, Cancer Chemotherapy and Pharmacology.

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

J. Schellens, J. Beijnen, A. Huitema, 2012, Pharmaceutical Research.

A Pharmacokinetic and Pharmacogenetic Study of Efavirenz in Children: Dosing Guidelines can Result in Subtherapeutic Concentrations

J. Beijnen, T. Kuijpers, A. Huitema, 2008, Antiviral therapy.

Increasing thyroid-stimulating hormone is associated with impaired glucose metabolism in euthyroid obese children and adolescents

J. Beijnen, M. Diamant, I. V. von Rosenstiel, 2013, Journal of pediatric endocrinology & metabolism : JPEM.

Limited value of routine microalbuminuria assessment in multi-ethnic obese children

J. Beijnen, M. Diamant, Nalini N. E. Radhakishun, 2013, Pediatric Nephrology.

RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics

J. Beijnen, R. Haas, F. Coevorden, 2020, Cancers.

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination

S. Rodenhuis, J. Beijnen, O. Tellingen, 2004, Cancer Chemotherapy and Pharmacology.

Modulation of the cytochrome P450–mediated metabolism of ifosfamide by ketoconazole and rifampin

J. Beijnen, A. Huitema, R. Mathôt, 2001, Clinical pharmacology and therapeutics.

The analysis of ifosfamide and its metabolites (review).

J. Beijnen, A. Bult, W. Underberg, 1993, Anticancer research.

Gas chromatographic determination of 2- and 3-dechloroethylifosfamide in plasma and urine.

H. Keizer, J. Beijnen, A. Bult, 1992, Journal of chromatography.

Ifosfamide metabolism and pharmacokinetics (review).

J. Beijnen, A. Bult, W. Underberg, 1994, Anticancer research.

Determination of 4-hydroxyifosfamide in biological matrices by high-performance liquid chromatography.

J. Beijnen, A. Bult, J. de Kraker, 1997, Journal of pharmaceutical and biomedical analysis.

Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology.

J. Schellens, J. Beijnen, R. Sparidans, 2016, Journal of pharmaceutical and biomedical analysis.

Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans.

H. Keizer, C. V. D. van de Velde, J. Beijnen, 1996, Cancer research.

Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.

J. Beijnen, M. Saag, F. Wit, 2006, AIDS research and human retroviruses.

Biodetermination of N-(deacetyl-O-4-vinblastoyl-23)-L-tryptophan, a metabolite of vintriptol, by high-performance liquid chromatography with fluorescence detection.

J. Beijnen, W. W. ten Bokkel Huinink, O. van Tellingen, 1992, Journal of chromatography.

High-performance liquid chromatographic determination of vinblastine, 4-O-deacetylvinblastine and the potential metabolite 4-O-deacetylvinblastine-3-oic acid in biological fluids.

J. Beijnen, W. W. ten Bokkel Huinink, O. van Tellingen, 1991, Journal of chromatography.

Bio-analysis of N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate, methane sulphonate (VileE) by high-performance liquid chromatography with fluorescence detection.

J. Beijnen, W. W. ten Bokkel Huinink, O. van Tellingen, 1990, Journal of pharmaceutical and biomedical analysis.

Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection.

J. Beijnen, O. van Tellingen, J. Burghouts, 1992, Journal of chromatography.

Phase I study of vintriptol, a tryptophan ester of vinblastine.

A. C. Dubbelman, J. Wanders, J. Beijnen, 1991, European journal of cancer.

High-performance liquid chromatographic bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug vintriptol.

J. Beijnen, W. W. ten Bokkel Huinink, O. van Tellingen, 1990, Journal of chromatography.

Screening for polymorphisms in the PXR gene in a Dutch population

J. Schellens, J. Beijnen, M. Deenen, 2006, European Journal of Clinical Pharmacology.

Drug interaction between St John's wort and nevirapine.

J. Beijnen, R. Mathôt, E. V. van Gorp, 2001, AIDS.

Factors Affecting Long-Term Safety of Trastuzumab in Patients with Early HER2-Positive Breast Cancer

J. Schellens, J. Beijnen, A. Boekhout, 2014 .

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry

J. Schellens, J. Beijnen, F. Stuurman, 2017, Thrombosis and Haemostasis.

New cytotoxic drugs and targets in oncology

J. Beijnen, 1992, Pharmaceutisch Weekblad.

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

H. Keizer, J. Schellens, J. Beijnen, 2000, British journal of clinical pharmacology.

Capecitabine induces severe angina-like chest pain.

J. Schellens, J. Beijnen, H. Boot, 2004, Annals of internal medicine.

Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.

J. Beijnen, R. Mathijssen, P. de Bruijn, 2014, British journal of clinical pharmacology.

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

C. Seynaeve, J. Verweij, J. Beijnen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Race Is Not Associated with Nevirapine Pharmacokinetics

J. Beijnen, F. Wit, A. Huitema, 2004, Therapeutic drug monitoring.

The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.

C. Damen, J. Schellens, H. Rosing, 2009, Journal of pharmaceutical and biomedical analysis.

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2018, Investigational New Drugs.

P-Glycoprotein, Multidrug-Resistance Associated Protein 2, Cyp3a, and Carboxylesterase Affect the Oral Availability and Metabolism of Vinorelbine

C. Damen, J. Beijnen, A. Schinkel, 2012, Molecular Pharmacology.

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice

J. Schellens, H. Rosing, J. Beijnen, 2010, Investigational New Drugs.

OATP1B1 mediates transport of gimatecan and BNP1350 and can be inhibited by several classical ABCB1 and/or ABCG2 inhibitors

J. Schellens, J. Beijnen, A. Schinkel, 2008 .

Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).

J. Beijnen, A. Schinkel, E. Wagenaar, 2017, Molecular pharmaceutics.

P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.

H. Rosing, J. Beijnen, A. Schinkel, 2015, Molecular pharmaceutics.

Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

J. Schellens, J. Beijnen, J. Beumer, 2007, Investigational New Drugs.

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

J. Beijnen, P. Borst, A. Schinkel, 1997, The Journal of clinical investigation.

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.

J. Beijnen, A. Schinkel, E. Wagenaar, 2018, Molecular pharmaceutics.

Individual and combined roles of CYP3A, P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel

H. Rosing, J. Beijnen, A. Schinkel, 2010, International journal of cancer.

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide

J. Beijnen, O. van Tellingen, A. Schinkel, 2009, Clinical Cancer Research.

ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity

H. Rosing, J. Beijnen, A. Schinkel, 2009, Clinical Cancer Research.

Metabolism of paclitaxel in mice

J. Schellens, J. Beijnen, O. van Tellingen, 2003, Anti-cancer drugs.

No relation between docetaxel administration route and high‐grade diarrhea incidence

J. Schellens, H. Rosing, J. Beijnen, 2020, Pharmacology research & perspectives.

Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

A. C. Dubbelman, S. Rodenhuis, J. Beijnen, 1992, British Journal of Cancer.

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

J. Schellens, J. Beijnen, T. Dorlo, 2017, Clinical Pharmacokinetics.

Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.

G. Giaccone, O. Dalesio, P. Postmus, 1995, Seminars in oncology.

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid

J. Schellens, J. Beijnen, D. Pluim, 2019, Journal of pharmaceutical and biomedical analysis.

Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin.

J. Schellens, J. Beijnen, E. Voest, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours

H. Rosing, J. Beijnen, A. Huitema, 2021, Drugs in R&D.

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

J. Beijnen, A. Bergman, M. Keessen, 2021, Cancer reports.

Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir

J. Schellens, J. Beijnen, A. Huitema, 2020, Investigational New Drugs.

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development

J. Schellens, J. Beijnen, A. Huitema, 2019, Journal of clinical pharmacology.

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model

J. Schellens, H. Rosing, J. Beijnen, 2016, International journal of cancer.

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer

J. Schellens, J. Beijnen, S. Rottenberg, 2015, The AAPS Journal.

Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review

J. Schellens, J. Beijnen, Vincent A de Weger, 2014, Anti-cancer drugs.

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation

J. Schellens, H. Rosing, J. Beijnen, 2014, British Journal of Cancer.

Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2009, Clinical Cancer Research.

The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice

J. Beijnen, O. van Tellingen, R. R. Press, 2006, Cancer Chemotherapy and Pharmacology.

Metabolism of docetaxel in mice

J. Schellens, J. Beijnen, M. Hillebrand, 2005, Cancer Chemotherapy and Pharmacology.

Steady‐State Pharmacokinetics of Twice‐Daily Dosing of Saquinavir Plus Ritonavir in HIV‐1‐Infected Individuals

J. Beijnen, J. Lange, J. Mulder, 2001, Journal of Acquired Immune Deficiency Syndromes.

Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis.

J. Beijnen, M. Wauben, G. Storm, 2011, International journal of pharmaceutics.

High Concentration of Daunorubicin and Daunorubicinol in Human Malignant Astrocytomas after Systemic Administration of Liposomal Daunorubicin

S. Leenstra, D. Troost, P. C. de Witt Hamer, 2001, Journal of Neuro-Oncology.

Degradation Kinetics of Three Gonadorelin Analogues: Developing a Method for Calculating Epimerization Parameters

J. Beijnen, A. Bult, W. Underberg, 1998, Pharmaceutical Research.

Degradation of azaglycinamido residues in model tripeptides derived from goserelin.

J. Beijnen, M. Tibben, J. Kruijtzer, 2000, Journal of pharmaceutical sciences.

A general approach to the interpretation of pH degradation profiles

J. Beijnen, A. Bult, O. V. D. Houwen, 1988 .

Malignant effusions contain lysophosphatidic acid (LPA)-like activity.

S. Rodenhuis, O. Dalesio, J. Beijnen, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.

J. Schellens, H. Rosing, J. Beijnen, 2013, Biomedical chromatography : BMC.

Gemcitabine a nd P aclitaxel: P harmacokinetic and P harmacodynamic I nteractions i n P atients With N on-Small-Cell L ung C ancer

G. Peters, G. Giaccone, E. Smit, 1999 .

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.

G. Peters, G. Giaccone, E. Smit, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

J. Beijnen, A. Schinkel, R. Sparidans, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, R. Sparidans, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.

J. Beijnen, R. Sparidans, M. V. van Haren, 2020, Journal of pharmaceutical and biomedical analysis.

Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma.

H. Rosing, J. Beijnen, A. Huitema, 2019, Journal of pharmaceutical and biomedical analysis.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces an

J. Schellens, H. Rosing, J. Beijnen, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.

J. Schellens, J. Beijnen, A. Schinkel, 2016, Journal of pharmaceutical and biomedical analysis.

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies

R. Obach, J. Wanders, J. Schellens, 2010, Investigational New Drugs.

Human metabolism of [14C]indisulam following i.v. infusion in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2005, Investigational New Drugs.

CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis

J. Baars, J. Beijnen, A. Huitema, 2011 .

Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.

H. Rosing, J. Beijnen, T. Dorlo, 2022, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.

J. Beijnen, P. D. de Vries, A. Huitema, 2014, The Journal of infectious diseases.

Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.

H. Rosing, J. Beijnen, A. Huitema, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells.

J. Schellens, J. Beijnen, R. Sparidans, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

H. Rosing, J. Beijnen, Cocky J F de Wolf, 2007, Rapid communications in mass spectrometry : RCM.

Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2006, Journal of mass spectrometry : JMS.

Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method.

J. Schellens, H. Rosing, J. Beijnen, 2009, Journal of chromatography. A.

Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2009, Rapid communications in mass spectrometry : RCM.

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

J. Beijnen, D. Brandsma, M. V. van Bussel, 2019, BMC Cancer.

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion

J. Baars, J. Beijnen, A. Huitema, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.

J. Baars, J. Beijnen, A. Huitema, 2011, Human antibodies.

The effect of admission to a geriatric ward on medication use: 2002 versus 1985

J. Beijnen, J. V. van Campen, L. Tulner, 2006, Pharmacoepidemiology and drug safety.

Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study.

S. Linn, J. Schellens, H. Rosing, 2015, Therapeutic drug monitoring.

A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.

S. Linn, J. Beijnen, T. Dahhan, 2013, Human reproduction.

Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

S. Linn, J. Schellens, H. Rosing, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

J. Schellens, J. Beijnen, A. Huitema, 2017, Clinical Pharmacokinetics.

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

Influence of Cremophor EL on the quantification of paclitaxel in plasma using high-performance liquid chromatography with solid-phase extraction as sample pretreatment.

H. Rosing, J. Beijnen, M. Huizing, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

J. Beijnen, P. Borst, O. van Tellingen, 1996, Journal of the National Cancer Institute.

Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.

J. Beijnen, O. van Tellingen, T. Buckle, 2007, Biomedical chromatography : BMC.

MINIREVIEW P Glycoprotein in Human Immunodeﬁciency Virus Type 1 Infection and Therapy

J. Beijnen, A. Schinkel, J. Lange, 2004 .

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

J. Schellens, H. Rosing, J. Beijnen, 2002, Cancer Chemotherapy and Pharmacology.

Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.

J. Schellens, H. Rosing, J. Beijnen, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Clinical Pharmacokinetics of Topotecan

J. Beijnen, W. W. Bokkel Huinink, V. Herben, 1996, Clinical pharmacokinetics.

Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction.

H. Rosing, J. Beijnen, W. W. ten Bokkel Huinink, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines

J. Schellens, J. Beijnen, L. M. Henricks, 2016, Cancer Chemotherapy and Pharmacology.

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

J. Schellens, J. Beijnen, D. Pluim, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cisplatin resistance and DNA repair.

J. Schellens, J. Beijnen, M. Maliepaard, 1997, Cancer Treatment Reviews.

Electrochemistry of potentially bioreductive alkylating quinones. Part 4. Qualitative and quantitative structure-activity relationships of aziridinylquinones

D. Reinhoudt, W. Verboom, J. Beijnen, 2010 .

Systematic interpretation of pH-degradation profiles. A critical review

J. Beijnen, A. Bult, O. V. D. Houwen, 1997 .

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review

J. Beijnen, A. Huitema, T. Dorlo, 2021, Clinical Pharmacokinetics.

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

Jos H. Beijnen, Alfred H. Schinkel, J. Beijnen, 2010, Molecular Cancer Therapeutics.

High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma.

J. Beijnen, E. Bekos, R. Gaver, 1993, Journal of chromatography.

RT-PCR detection of respiratory pathogens in newborn children admitted to a neonatal medium care unit

J. Beijnen, E. Claas, J. Mulder, 2012, Pediatric Research.

Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules

J. Beijnen, M. Hillebrand, A. Bult, 1996, Antimicrobial agents and chemotherapy.

HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections

J. Beijnen, R. Geskus, R. Coutinho, 2002, AIDS.

A phase I and pharmacokinetic study of intraperitoneal topotecan

H. Rosing, J. Beijnen, P. Willemse, 2001, British Journal of Cancer.

Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients

H. Rosing, J. Beijnen, R. Mathijssen, 2020, Clinical Pharmacokinetics.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS

J. Schellens, H. Rosing, J. Beijnen, 2017, Therapeutic drug monitoring.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

J. Schellens, J. Beijnen, R. Mathijssen, 2016, Clinical Cancer Research.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

J. Schellens, H. Rosing, J. Beijnen, 2016, Bioanalysis.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.

J. Schellens, J. Beijnen, R. Sparidans, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients?

P. Reiss, J. Beijnen, F. Wit, 2000 .

Clinical research on antiangiogenic therapy.

J. Schellens, J. Beijnen, E. Voest, 1998, Pharmacological research.

Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series

H. Rosing, J. Beijnen, F. Amant, 2022, Clinical pharmacology and therapeutics.

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV‐care

J. Beijnen, A. Huitema, A. Boer, 2004, Journal of clinical pharmacy and therapeutics.

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure

J. Beijnen, A. Schinkel, R. Sparidans, 2022, Pharmaceuticals.

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

S. Linn, J. Schellens, J. Beijnen, 2019, International journal of cancer.

Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2014, Biomedical chromatography : BMC.

Solubility and bioavailability improvement of pazopanib hydrochloride

J. Schellens, J. Beijnen, A. Huitema, 2018, International journal of pharmaceutics.

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

J. Schellens, J. Beijnen, R. Mathijssen, 2017, Clinical Pharmacokinetics.

Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.

J. Schellens, H. Rosing, J. Beijnen, 2004, Biomedical chromatography : BMC.

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

P. Moeskops, E. Smit, J. Beijnen, 2022, Pharmaceutical Research.

A phase Istudy ofprolonged continuous infusion oflowdoserecombinant interleukin-2 inmelanoma andrenal cellcancer.PartI:clinical aspects

A. C. Dubbelman, S. Rodenhuis, J. Beijnen, 1992 .

Inhibitors of mTOR.

J. Schellens, J. Beijnen, H. Gurney, 2010, The oncologist.

Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons.

J. Beijnen, A. Bult, P. Meenhorst, 2002, Pharmacological research.

Process characterisation, optimisation and validation of production of diacetylmorphine/caffeine sachets: a design of experiments approach.

W. van den Brink, J. Beijnen, B. Nuijen, 2004, International journal of pharmaceutics.

2-hydroxypropyl-β-cyclodextrin extracts 2-phenylphenol from silicone tubing

J. Beijnen, M. Hillebrand, B. Nuijen, 2004 .

1577PGERMLINE TYMS GENOTYPE IS HIGHLY PREDICTIVE IN PATIENTS WITH ADVANCED COLORECTAL AND GASTROESOPHAGEAL CANCER INDEPENDENT OF FLUOROPYRIMIDINE PHARMACOLOGY: RESULTS FROM TWO PROSPECTIVE TRANSLATIONAL STUDIES.

J. Schellens, H. Rosing, J. Beijnen, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

J. Schellens, H. Rosing, J. Beijnen, 2013, Cancer Chemotherapy and Pharmacology.

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer

J. Beijnen, A. Huitema, D. van den Broek, 2022, Clinical and translational science.

Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices.

J. Beijnen, B. Nuijen, J. L. García, 2006, Die Pharmazie.

Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.

J. Beijnen, B. Nuijen, E. Millán, 2005, PDA journal of pharmaceutical science and technology.

Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2003, Journal of mass spectrometry : JMS.

Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

T. D. de Reijke, J. Schellens, J. Beijnen, 2005, Clinical Cancer Research.

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of mass spectrometry : JMS.

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

J. Beijnen, A. Huitema, E. van Werkhoven, 2022, BMC cancer.

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Y. Bang, J. Schellens, J. Beijnen, 2015, British journal of clinical pharmacology.

Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.

J. Beijnen, C. Zwaan, A. Huitema, 2020, Clinical pharmacology and therapeutics.

Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.

J. Schellens, J. Beijnen, S. Leijen, 2010, Current clinical pharmacology.

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen

S. Rodenhuis, J. Schellens, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

H. Rosing, J. Beijnen, B. Davies, 1995, Journal of chromatography. B, Biomedical applications.

Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.

G. Peters, G. Giaccone, J. Beijnen, 1994, Biochemical pharmacology.

Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 1998, Pharmacy World and Science.

Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution.

J. Beijnen, B. R. Smith, W. Underberg, 1990, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer

H. Rosing, J. Beijnen, D. Tsiftsis, 2003, Anti-cancer drugs.

Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy

S. Rodenhuis, J. Beijnen, W. Moolenaar, 2000, Cancer Chemotherapy and Pharmacology.

Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry

J. Schellens, J. Beijnen, M. Tibben, 2000, Fresenius' journal of analytical chemistry.

Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Therapeutic drug monitoring.

Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma

J. Schellens, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

J. Beijnen, A. Sparreboom, O. van Tellingen, 1996, Drug metabolism and disposition: the biological fate of chemicals.

Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?

J. Schellens, H. Rosing, J. Beijnen, 2011, Fundamental & clinical pharmacology.

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

W. M. Smit, J. Schellens, J. Beijnen, 2009, The oncologist.

Gemcitabine metabolite, 2’,2’-difluorodeoxyuridine (dFdU), can be phosphorylated and incorporated into nucleic acids

J. Schellens, J. Beijnen, D. Pluim, 2007 .

Neoadjuvant Systemic Treatment of Primary Angiosarcoma

J. Beijnen, W. T. van der Graaf, W. V. van Houdt, 2020, Cancers.

Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin

S. Rodenhuis, J. Beijnen, R. Maes, 1995, Cancer Chemotherapy and Pharmacology.

Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer.

S. Rodenhuis, J. Beijnen, W. W. ten Bokkel Huinink, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Pharmacology of Carboplatin Administered in Alternating Sequence with Paclitaxel in Patients with Non-Small Cell Lung Cancer: A European Cancer Centre (ECC) Study

G. Giaccone, P. Postmus, J. Beijnen, 1996 .

The risks of handling cytotoxic drugs

J. Beijnen, W. Underberg, G. Kaijser, 1990, Pharmaceutisch Weekblad.

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F

J. Schellens, J. Beijnen, J. Jimeno, 2001, Anti-cancer drugs.

The intravenous to oral switch of taxanes: strategies and current clinical developments.

J. Beijnen, A. Bergman, Marit A. C. Vermunt, 2020, Future oncology.

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

J. Schellens, J. Beijnen, A. Zandvliet, 2011, Investigational New Drugs.

Effect of Mycophenolate Mofetil on the Pharmacokinetics of Antiretroviral Drugs and on Intracellular Nucleoside Triphosphate Pools

J. Beijnen, A. Huitema, D. Back, 2004, Clinical pharmacokinetics.

Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.

F. van Coevorden, J. Beijnen, F. Coevorden, 2001, European journal of cancer.

The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry.

C. Damen, J. Schellens, H. Rosing, 2009, Biomedical chromatography : BMC.

A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

C. Damen, J. Schellens, H. Rosing, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients.

H. Rosing, J. Beijnen, R. Gijn, 1991, Journal of pharmaceutical and biomedical analysis.

High-performance liquid chromatographic bioanalysis of anthracycline cytostatic drugs.

J. Beijnen, W. Underberg, 1988, Journal of pharmaceutical and biomedical analysis.

Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.

J. Schellens, H. Rosing, J. Beijnen, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)

J. Beijnen, A. Schinkel, S. Durmuş, 2014, Pharmaceutical Research.

Stable and sensitive method for the simultaneous determination of N5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids.

J. Beijnen, O. van Tellingen, H. van der Woude, 1989, Journal of chromatography.

Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).

W. Humphreys, J. Beijnen, J. Beumer, 2009, Drug metabolism and pharmacokinetics.

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine

J. Schellens, H. Rosing, J. Beijnen, 2011, Cancer Chemotherapy and Pharmacology.

Long-term platinum retention after treatment with cisplatin and oxaliplatin

J. Schellens, J. Beijnen, A. Huitema, 2008, BMC clinical pharmacology.

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours

J. Schellens, H. Rosing, J. Beijnen, 2007, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

J. Beijnen, A. Huitema, G. Sonke, 2022, Clinical pharmacokinetics.

Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells

J. Schellens, J. Beijnen, Anna Tzani, 2018, Nucleosides, nucleotides & nucleic acids.

Hepatitis during Chloroguanide Prophylaxis

J. Beijnen, J. Mulder, Lonneke MM Oostweegel, 1998, The Annals of pharmacotherapy.

Is age just a number? A population pharmacokinetic study of gemcitabine

J. Beijnen, A. Huitema, N. Steeghs, 2022, Cancer Chemotherapy and Pharmacology.

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”

J. Schellens, J. Beijnen, A. Huitema, 2015, BioMed research international.

Identifying the metabolic syndrome in obese children and adolescents: do age and definition matter?

J. Beijnen, M. Diamant, R. K. Schindhelm, 2009, Current clinical pharmacology.

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

J. Beijnen, A. Huitema, A. D. V. de Vries Schultink, 2018, Breast.

Didanosine, a new antiretroviral drug

J. Beijnen, R. Franssen, P. Meenhorst, 1992, Pharmaceutisch Weekblad.

Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

J. Schellens, J. Beijnen, D. Pluim, 2015, Bioanalysis.

A systematic study on the chemical stability of the novel indoloquinone antitumour agent EO9

J. Beijnen, R. Henrar, W. Underberg, 1993 .

Toxicokinetics of a dipyridamole (Persantin) intoxication: Case report

J. Beijnen, J. S. Lagas, D. Brandjes, 2011, Human & experimental toxicology.

Study on didanosine concentrations in cerebrospinal fluid

J. Beijnen, J. Mulder, R. Hoetelmans, 1995, Pharmacy World and Science.

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer

H. Rosing, J. Beijnen, R. Mathijssen, 2021, Clinical pharmacology and therapeutics.

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

J. Schellens, J. Beijnen, A. Huitema, 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Pharmacokinetics of Zidovudine and Acetaminophen in a Patient on Chronic Acetaminophen Therapy

J. Beijnen, D. Burger, P. Meenhorst, 1994, The Annals of pharmacotherapy.

Does antisense make sense?

J. Beijnen, 1993, Pharmacy World and Science.

Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity.

J. Engbersen, T. Schumacher, J. Beijnen, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry

H. Rosing, J. Beijnen, M. Hillebrand, 2019, Analytical and Bioanalytical Chemistry.

Stabilization of daunorubicin and 4-demethoxydaunorubicin on complexation with octakis(2,6-di-O-methyl)-γ-cyclodextrin in acidic aqueous solution

J. Beijnen, M. Otagiri, K. Koizumi, 1992 .

Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs.

H. Rosing, J. Beijnen, E. Stokvis, 2005, Mass spectrometry reviews.

Thermal stability study of crystalline and novel spray‐dried amorphous nilotinib hydrochloride

J. Schellens, J. Beijnen, H. Vromans, 2018, Journal of pharmaceutical and biomedical analysis.

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

J. Schellens, H. Rosing, J. Beijnen, 2019, CPT: pharmacometrics & systems pharmacology.

Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis

J. Schellens, J. Beijnen, A. de Boer, 2019, International journal of cancer.

Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response

Marijn T. M. van Jaarsveld, H. Rosing, J. Beijnen, 2014, Nature Communications.

Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes.

J. Beijnen, G. Storm, B. Nuijen, 2012, International journal of pharmaceutics.

Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells

J. Schellens, J. Beijnen, D. Pluim, 2013, Analytical and Bioanalytical Chemistry.

Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors

J. Schellens, J. Beijnen, L. Weiner, 2010, European Journal of Drug Metabolism and Pharmacokinetics.

The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer

J. Beijnen, A. Huitema, M. Soesan, 2022, Breast Cancer Research and Treatment.

Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

J. Schellens, H. Rosing, J. Beijnen, 1998, Anti-cancer drugs.

Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

2',3'-dideoxyinosine (ddI): its chemical stability and cyclodextrin complexation in aqueous media.

J. Beijnen, D. Burger, O. Bekers, 1993, Journal of pharmaceutical and biomedical analysis.

Computation of mitomycin C-γ-cyclodextrin complex stability constant

J. Beijnen, A. Bult, O. Bekers, 1993 .

A general approach to the interpretation of pH degradation profiles in the presence of ligands

J. Beijnen, A. Bult, O. Bekers, 1991 .

Population Pharmacokinetics of Intracellular 5-Fluorouridine 5′-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine

J. Beijnen, A. Huitema, S. Marchetti, 2021, The AAPS journal.

Bioanalysis of radioiodine labelled meta-iodobenzylguanidine, its metabolites and free radioiodide in body fluids

A. Wafelman, J. Beijnen, C. Hoefnagel, 1997 .

Efficacy and Tolerability of a High Loading Dose (25,000 IU Weekly) Vitamin D3 Supplementation in Obese Children with Vitamin D Insufficiency/Deficiency

J. Beijnen, M. Diamant, I. V. von Rosenstiel, 2014, Hormone Research in Paediatrics.

[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].

J. Schellens, J. Beijnen, M. Deenen, 2012, Nederlands tijdschrift voor geneeskunde.

Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy.

J. Schellens, J. Beijnen, J. Severens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial

W. Dreschler, M. Hauptmann, J. Schellens, 2021, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

J. Beijnen, A. Schinkel, Nancy H. C. Loos, 2022, International journal of molecular sciences.

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

J. Schellens, J. Beijnen, A. Huitema, 2013, British journal of clinical pharmacology.

High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.

J. Beijnen, D. Sherris, O. van Tellingen, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study

J. Beijnen, A. Bergman, A. Huitema, 2019, Pharmaceutical Research.

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort

J. Schellens, J. Beijnen, A. Huitema, 2019, Cancer medicine.

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

J. Beijnen, A. Huitema, N. Steeghs, 2022, Frontiers in Oncology.

Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.

J. Schellens, J. Beijnen, J. Molenaar, 2014, Journal of pharmaceutical and biomedical analysis.

Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.

J. Beijnen, P. D. de Vries, A. Huitema, 2012, The Journal of antimicrobial chemotherapy.

Transplacental Transfer of Paclitaxel, Docetaxel, Carboplatin, and Trastuzumab in a Baboon Model

J. Beijnen, R. Devlieger, F. Amant, 2010, International Journal of Gynecologic Cancer.

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma – drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study

J. Beijnen, J. Mulder, R. Hoetelmans, 1999, Cancer Chemotherapy and Pharmacology.

Rapid Detection of the DPYD IVS14+1G>A Mutation for Screening Patients to Prevent Fluorouracil-Related Toxicity

J. Schellens, J. Beijnen, A. Cats, 2012, Molecular Diagnosis & Therapy.

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, A. Schinkel, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

J. Schellens, J. Beijnen, A. Bergamo, 2012, Journal of inorganic biochemistry.

Processing of Doxorubicin-Containing Liposomes by Liver Macrophages in Vitro

J. Beijnen, G. Storm, J. Regts, 1989 .

Morphine Induces Hyperalgesia without Involvement of µ-Opioid Receptor or Morphine-3-glucuronide

A. Dahan, J. Beijnen, Amanda R. Waxman, 2012, Molecular medicine.

Liposomal drug formulations in the treatment of rheumatoid arthritis.

J. Beijnen, G. Storm, B. Nuijen, 2011, Molecular pharmaceutics.

Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2005, Biomedical chromatography : BMC.

PERFORMANCE OF THE ANALYTICAL ASSAYS OF PACLITAXEL, DOCETAXEL, AND CYCLOSPORIN A IN A ROUTINE HOSPITAL LABORATORY SETTING

J. Schellens, H. Rosing, J. Beijnen, 2001 .

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion

S. Rodenhuis, J. Schellens, H. Rosing, 2000, Cancer Chemotherapy and Pharmacology.

Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280.

J. Beijnen, J. Rice, J. Reedijk, 2003, PDA journal of pharmaceutical science and technology.

Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Investigational Polymer-Conjugated Platinum Anticancer Agent AP 5280

J. Beijnen, J. Rice, H. Talsma, 2003, Drug development and industrial pharmacy.

Penetration of Idarubicin into Malignant Brain Tumor Tissue

J. Beijnen, W. Boogerd, M. M. van de Sandt, 1999, Journal of Neuro-Oncology.

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

S. Sundar, J. Beijnen, A. Huitema, 2021, Clinical Pharmacokinetics.

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib

J. Beijnen, A. Huitema, A. Schinkel, 2020, Clinical Pharmacokinetics.

Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism

I. Huijbers, H. Rosing, J. Beijnen, 2022, Acta pharmaceutica Sinica. B.

Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer.

J. Bussink, C. Punt, J. Beijnen, 2008, Lung cancer.

Hypersensitivity Reactions to Etoposide

J. Beijnen, J. Schornagel, R. Hoetelmans, 1996, The Annals of pharmacotherapy.

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands

J. Verweij, J. Beijnen, W. W. ten Bokkel Huinink, 2000, Anti-Cancer Drugs.

Limited Sampling Models for the Pharmacokinetics of Docetaxel

A. C. Dubbelman, H. Rosing, J. Beijnen, 1997 .

The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [177Lu]Lu-HA-DOTA-TATE in pharmaceutical preparations.

J. Beijnen, L. van Andel, E. Aalbersberg, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces

J. Beijnen, A. Sparreboom, O. Tellingen, 1995, Cancer Chemotherapy and Pharmacology.

Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.

G. Giaccone, O. Dalesio, P. Postmus, 1994, Seminars in oncology.

Erlotinib and pantoprazole: a relevant interaction or not?

J. Beijnen, R. ter Heine, M. Malingré, 2010, British journal of clinical pharmacology.

Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer.

J. Schellens, J. Beijnen, A. Cats, 2010, Cancer biomarkers : section A of Disease markers.

Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer.

E. Smit, J. Beijnen, D. Sleijfer, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

J. Beijnen, R. Mathijssen, A. Huitema, 2019, Pharmaceutical Research.

Alternative formulations of paclitaxel.

J. Beijnen, B. Nuijen, W. W. Huinink, 1997, Cancer treatment reviews.

Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS.

J. Schellens, H. Rosing, J. Beijnen, 2014, Biomedical chromatography : BMC.

A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2006, Biomedical chromatography : BMC.

A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.

H. Rosing, J. Beijnen, O. van Tellingen, 2004, Journal of mass spectrometry : JMS.

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.

J. Beijnen, W. W. ten Bokkel Huinink, J. Vermorken, 1997, Seminars in oncology.

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

H. Rosing, J. Beijnen, W. W. ten Bokkel Huinink, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry.

J. Schellens, J. Beijnen, J. D. de Vos, 2011, Journal of analytical toxicology.

Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry.

J. Schellens, J. Beijnen, J. D. de Vos, 2011, Journal of pharmaceutical and biomedical analysis.

Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?

J. Schellens, J. Beijnen, M. Deenen, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

J. Schellens, J. Beijnen, A. Bergman, 2019, Drugs & Aging.

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

H. Rosing, J. Beijnen, A. Bergman, 2022, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet

J. Schellens, J. Beijnen, A. Huitema, 2013, Drug Delivery and Translational Research.

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of pharmaceutical and biomedical analysis.

PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study

J. Beijnen, R. Haas, A. Huitema, 2020, BMJ Open.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.

J. Beijnen, G. Sava, B. Nuijen, 2002, International journal of pharmaceutics.

Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study

F. van Leth, J. Beijnen, T. Macgregor, 2005, HIV clinical trials.

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.

J. Beijnen, A. Huitema, F. de Wolf, 2005, Journal of acquired immune deficiency syndromes.

Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs

J. Beijnen, A. Huitema, J. Mulder, 2004, Clinical pharmacokinetics.

Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals

J. Beijnen, A. Huitema, J. Mulder, 2003, Clinical drug investigation.

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

J. Schellens, J. Beijnen, O. van Tellingen, 2009, Current clinical pharmacology.

Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA).

J. Beijnen, M. J. Maanen, C. Smeets, 2000, Cancer treatment reviews.

Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV‐1 infected individuals

P. Reiss, J. Beijnen, J. Lange, 1998, AIDS.

Sensitive Determination of the Carboxylate and Lactone Forms of the Novel Antitumor Drug Irinotecan and Its Active Metabolite in Plasma by HPLC

J. Schellens, H. Rosing, J. Beijnen, 1998 .

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)

J. Beijnen, A. Schinkel, S. Durmuş, 2015, Pharmaceutical Research.

Co-trimoxazole and stavudine interference in a high-performance liquid chromatographic analysis for didanosine in human plasma.

J. Beijnen, J. Mulder, R. Hoetelmans, 1998, Therapeutic drug monitoring.

Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

J. Schellens, J. Beijnen, K. Heinhuis, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde.

J. Beijnen, R. Hoetelmans, R. Sparidans, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer

H. Rosing, J. Beijnen, A. Huitema, 2019, Investigational New Drugs.

Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2017, Investigational New Drugs.

Bioanalytical aspects of clinical mass balance studies in oncology.

A. C. Dubbelman, J. Schellens, H. Rosing, 2011, Bioanalysis.

Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)

J. Beijnen, A. Schinkel, S. Durmuş, 2014, Pharmaceutical Research.

A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2009, Biomedical chromatography : BMC.

Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically.

J. Schellens, H. Rosing, J. Beijnen, 2008, Rapid communications in mass spectrometry : RCM.

Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2007, Rapid communications in mass spectrometry : RCM.

Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan

H. Rosing, J. Beijnen, V. Herben, 1997, Cancer Chemotherapy and Pharmacology.

The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma.

H. Rosing, J. Beijnen, E. Doyle, 1996, Journal of pharmaceutical and biomedical analysis.

Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care

S. Linn, J. Schellens, H. Rosing, 2014, Breast Cancer Research and Treatment.

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

S. Rodenhuis, J. Verweij, J. Schellens, 1996, Cancer Chemotherapy and Pharmacology.

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.

S. Rodenhuis, J. Beijnen, W. W. ten Bokkel Huinink, 1990, Journal of pharmaceutical and biomedical analysis.

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.

J. Beijnen, H. Klomp, A. Huitema, 2015, Clinical lung cancer.

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

J. Beijnen, P. Baas, J. Burgers, 2022, Pharmaceutical Research.

Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review).

J. Beijnen, O. van Tellingen, W. Nooijen, 1992, Anticancer research.

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice

J. Schellens, J. Beijnen, J. Garrigue, 2010, Investigational New Drugs.

Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2006, Analytical biochemistry.

Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels.

J. Beijnen, A. Huitema, J. V. van Woensel, 2011, Journal of child and adolescent psychopharmacology.

Inducing synthetic lethality using PARP inhibitors.

J. Schellens, J. Beijnen, D. Boss, 2010, Current clinical pharmacology.

DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.

J. Beijnen, J. Haanen, K. Oosterhuis, 2009, Journal of controlled release : official journal of the Controlled Release Society.

Optimization of intradermal vaccination by DNA tattooing in human skin.

T. Schumacher, J. Beijnen, W. Hennink, 2008, Human gene therapy.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

W. V. van Harten, T. Schumacher, J. Beijnen, 2022, The New England journal of medicine.

Population Pharmacokinetics of Heroin and its Major Metabolites

E. J. Rook, J. M. Ree, J. Beijnen, 2006, Clinical pharmacokinetics.

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs

J. Beijnen, A. Huitema, A. Schinkel, 2022, Pharmaceuticals.

Renal excretion of iodine-131 labelledmeta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours

A. Wafelman, J. Beijnen, C. Hoefnagel, 1997, European Journal of Nuclear Medicine.

Gas chromatographic analysis, with electron capture detection, of the antifungal drug fluconazole in microvolumes of human plasma.

J. Beijnen, W. Underberg, P. Meenhorst, 1991, Journal of pharmaceutical and biomedical analysis.

Prevalence of Xerostomia and Its Relationship with Underlying Diseases, Medication, and Nutrition: A Descriptive Observational Study

J. Beijnen, L. Tulner, J. Eijk, 2013, Journal of the American Geriatrics Society.

Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.

J. Beijnen, W. W. ten Bokkel Huinink, F. Zoetmulder, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Population Pharmacokinetics of Ifosfamide and its Dechloroethylated and Hydroxylated Metabolites in Children with Malignant Disease

J. Beijnen, R. Mathôt, T. Kerbusch, 2001, Clinical pharmacokinetics.

Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting

L. Lagae, J. Beijnen, F. Amant, 2009, International Journal of Gynecologic Cancer.

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Jos H. Beijnen, Ron J. Keizer, Michel van Benten, 2011, Comput. Methods Programs Biomed..

Heroin-assisted treatment in the Netherlands: History, findings, and international context

E. J. Rook, J. M. Ree, J. Beijnen, 2010, European Neuropsychopharmacology.

Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients.

W. van den Brink, J. Beijnen, J. van Ree, 2005, Drug and alcohol dependence.

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

J. Schellens, J. Beijnen, F. Amant, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

J. Beijnen, G. Halbert, J. Slack, 1995, British Journal of Cancer.

Propofol extravasation in a breast cancer patient

J. Baars, J. Schellens, J. Beijnen, 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Effect of Cisplatin-Containing Chemotherapy on Lithium Serum Concentrations

S. Rodenhuis, J. Wanders, J. Beijnen, 1992, The Annals of pharmacotherapy.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real‐world cohort study: does age matter?

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.

J. Schellens, J. Beijnen, J. Molenaar, 2014, Journal of pharmaceutical and biomedical analysis.

A rapid, simple and accurate method for the bioanalysis of zidovudine

J. Beijnen, O. Bekers, W. Underberg, 1989 .

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

J. Schellens, J. Beijnen, P. Baas, 2015, Investigational New Drugs.

Anthracycline antitumour agents

J. Beijnen, A. Bult, W. Underberg, 1986, Pharmaceutisch Weekblad.

The boosting of didanosine by allopurinol permits a halving of the didanosine dosage

J. Beijnen, A. Huitema, J. Lange, 2002, AIDS.

The effect of heptakis (2,6-di-O-methyl)-γ-cyclodextrin on mitomycin C stability in aqueous solution

J. Beijnen, M. Otagiri, K. Koizumi, 1990 .

Degradation of mitomycin C in acid phosphate and acetate buffer solutions

H. Rosing, J. Beijnen, R. Fokkens, 1986 .

Mitomycin antitumour agents: a review of their physico-chemical and analytical properties and stability.

J. Beijnen, H. Lingeman, W. Underberg, 1986, Journal of pharmaceutical and biomedical analysis.

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

J. Schellens, H. Rosing, J. Beijnen, 2009, Analytical and bioanalytical chemistry.

Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244)

J. Beijnen, A. Bult, R. Henrar, 2004, Investigational New Drugs.

Future opportunities in preventing cisplatin induced ototoxicity.

J. Schellens, J. Beijnen, A. Balm, 2006, Cancer treatment reviews.

Structure elucidation and characterization of daunorubicin degradation products

J. Beijnen, W. Underberg, R. D. Ooijen, 1987 .

Facile Small Scale Synthesis of Nucleoside 5′-Phosphate Mixtures

J. Schellens, H. Rosing, J. Beijnen, 2010, Nucleosides, nucleotides & nucleic acids.

LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products.

J. Beijnen, M. Hillebrand, C. Lutz, 2005, Journal of pharmaceutical and biomedical analysis.

Cyclodextrins in the Pharmaceutical Field

Jos H. Beijnen, Auke Bult, J. Beijnen, 1991 .

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.

Jos H Beijnen, Irene van den Broek, J. Schellens, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Abstracts of Dutch doctoral theses

R. A. Zeeuw, G. J. Jong, M. J. M. Zeeland, 2005, Pharmaceutisch Weekblad.

Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum.

J. Schellens, J. Beijnen, R. Sparidans, 2008, Rapid communications in mass spectrometry : RCM.

Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma.

J. Schellens, J. Beijnen, R. Sparidans, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, A. Huitema, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Analytical techniques used to study the degradation of proteins and peptides: chemical instability.

J. Beijnen, J. Marchal, A. Bult, 1998, Journal of pharmaceutical and biomedical analysis.

EFFECTS OF CYCLODEXTRINS ON N-TRIFLUOROACETYLDOXORUBICIN-14-VALERATE (AD-32) STABILITY AND SOLUBILITY IN AQUEOUS MEDIA

J. Beijnen, A. Bult, O. Bekers, 1991 .

The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.

J. Schellens, H. Rosing, J. Beijnen, 2008, Mass spectrometry reviews.

Inclusion complex formation of anthracycline antibiotics with cyclodextrins; a proton nuclear magnetic resonance and molecular modelling study

J. Beijnen, S. P. Helden, O. Bekers, 1991 .

Degradation kinetics of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) in aqueous solution in the presence of γ-cyclodextrin

J. Beijnen, A. Bult, O. Bekers, 1994 .

The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery

J. Schellens, J. Beijnen, O. van Tellingen, 2000, Investigational New Drugs.

Effect of cyclodextrins on anthracycline stability in acidic aqueous media

J. Beijnen, M. Otagiri, O. Bekers, 1988, Pharmaceutisch Weekblad.

Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

J. Schellens, H. Rosing, J. Beijnen, 2016, Investigational New Drugs.

Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.

H. Rosing, J. Beijnen, N. Venekamp, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography–inductively coupled plasma mass spectrometry

J. Schellens, J. Beijnen, A. Huitema, 2008, Anti-cancer drugs.

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

A. Paci, J. Beijnen, Nicolas Widmer, 2014, European journal of cancer.

Drug Interactions Between Antiretroviral Drugs and Comedicated Agents

J. Beijnen, A. Huitema, J. Mulder, 2003, Clinical pharmacokinetics.

The pharmacological role of P-glycoprotein in the intestinal epithelium.

J. Beijnen, O. van Tellingen, O. Tellingen, 1998, Pharmacological research.

Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry

J. Beijnen, O. Tellingen, R. Maes, 1995 .

Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma.

H. Rosing, J. Beijnen, J. Mbui, 2020, Journal of pharmaceutical and biomedical analysis.

Stability of corticosteroids under anaerobic conditions

J. Beijnen, D. Dekker, 1984, Pharmaceutisch Weekblad.

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

J. Schellens, J. Beijnen, D. Pluim, 2004, Cancer Chemotherapy and Pharmacology.

Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).

J. Schellens, J. Beijnen, R. Mazzanti, 2007, The oncologist.

Herb-drug interactions in oncology: focus on mechanisms of induction.

J. Schellens, J. Beijnen, I. Meijerman, 2006, The oncologist.

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

Jos H Beijnen, J. Beijnen, N. Zelcer, 2002, AIDS.

P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy

J. Beijnen, A. Schinkel, J. Prins, 2004, Antimicrobial Agents and Chemotherapy.

Pharmaceutical development of anticancer agents derived from marine sources

J. Schellens, J. Beijnen, J. Jimeno, 2000, Anti-cancer drugs.

High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients.

H. Rosing, J. Beijnen, A. Bult, 1995, Journal of chromatography. B, Biomedical applications.

Population Pharmacokinetics of Itraconazole in Thai HIV-1-Infected Persons

J. Beijnen, A. Huitema, J. Lange, 2003, Therapeutic drug monitoring.

Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients.

J. Beijnen, R. Sparidans, C. Koks, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

J. Schellens, J. Beijnen, A. Huitema, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

J. Beijnen, P. D. de Vries, M. Balasegaram, 2012, The Journal of antimicrobial chemotherapy.

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine

J. Beijnen, P. D. de Vries, Y. Stienstra, 2011, PLoS neglected tropical diseases.

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

J. Beijnen, A. Sparreboom, O. van Tellingen, 1996, Journal of chromatography. B, Biomedical applications.

The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS.

J. Schellens, H. Rosing, J. Beijnen, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Ocular complications of the acquired immunodeficiency syndrome

J. Beijnen, D. Burger, P. Meenhorst, 1993, Pharmacy World and Science.

Effects of Cyclosporine A on Single-Dose Pharmacokinetics of Intravenous Itraconazole in Patients With Hematologic Malignancies

J. Beijnen, P. Huijgens, T. M. Bosch, 2008, Therapeutic drug monitoring.

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.

J. Beijnen, J. Mulder, B. Kappelhoff, 2005, British journal of clinical pharmacology.

Mass Balance Studies, with a Focus on Anticancer Drugs

J. Schellens, J. Beijnen, J. Beumer, 2006, Clinical pharmacokinetics.

Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir.

J. Beijnen, J. V. D. van der Meer, J. Mulder, 2000, AIDS.

Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients.

J. Beijnen, J. Mulder, R. Hoetelmans, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV

J. Beijnen, J. Mulder, A. Bult, 1993, AIDS.

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.

J. Schellens, J. Beijnen, M. Deenen, 2006, Toxicology and applied pharmacology.

Incidence and risk factors for nevirapine-associated rash

J. Beijnen, A. Huitema, R. Heine, 2003, European Journal of Clinical Pharmacology.

Prognostic factors for the clinical effectiveness of fluconazole in the treatment of oral candidiasis in HIV-1-infected individuals.

J. Beijnen, J. Mulder, P. Meenhorst, 2002, Pharmacological research.

Can Fluconazole Concentrations in Saliva Be Used for Therapeutic Drug Monitoring?

J. Beijnen, R. Mathôt, R. Hoetelmans, 2001, Therapeutic drug monitoring.

Design of a drug‐drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation

J. Schellens, J. Beijnen, A. Huitema, 2014, Pediatric blood & cancer.

Drug interactions with zidovudine.

J. Beijnen, D. Burger, P. Meenhorst, 1993, AIDS.

Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement

J. Schellens, J. Beijnen, B. Nuijen, 2013, Clinical Pharmacokinetics.

Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.

Jos H Beijnen, Wim van den Brink, Alwin D R Huitema, 2006, Current clinical pharmacology.

Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.

E. J. Rook, W. van den Brink, J. Beijnen, 2006, Basic & clinical pharmacology & toxicology.

An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.

J. Beijnen, T. Dorlo, Semra Palić, 2021, International journal of antimicrobial agents.

Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.

H. Rosing, J. Beijnen, P. Houghton, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Determination of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of 3'-azido-3'-deoxythymidine, in human plasma by ion-pair high-performance liquid chromatography.

H. Rosing, J. Beijnen, A. Bult, 1993, Journal of chromatography.

Chemical stability of the antitumor drug mitomycin C in solutions for intravesical instillation.

J. Beijnen, W. Underberg, R. van Gijn, 1990, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

Discrepancies between Medical and Pharmacy Records for Patients on Anti-HIV Drugs

J. Beijnen, A. de Boer, R. Mathôt, 2002, The Annals of pharmacotherapy.

The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.

J. Beijnen, J. Mulder, R. Hoetelmans, 2001, British journal of clinical pharmacology.

The effect of ﬂuconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals

J. Beijnen, D. Burger, P. Koopmans, 2001 .

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Cancer Chemotherapy and Pharmacology.

Clinical pharmacology of anticancer agents in relation to formulations and administration routes.

J. Schellens, J. Beijnen, W. W. Huinink, 1999, Cancer treatment reviews.

Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.

R. Medema, J. Beijnen, E. Kalkhoven, 2011, Cancer cell.

An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

Jos H Beijnen, Irma Meijerman, J. Schellens, 2003, Toxicology and applied pharmacology.

Variability in bioavailability of small molecular tyrosine kinase inhibitors.

J. Schellens, J. Beijnen, B. Nuijen, 2015, Cancer treatment reviews.

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.

J. Beijnen, A. Schinkel, R. Sparidans, 2021, Pharmacological research.

Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow)

J. Beijnen, L. van Andel, M. Stokkel, 2020, EJNMMI Radiopharmacy and Chemistry.

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

T. Schumacher, M. V. van Buuren, J. Beijnen, 2020, Journal for ImmunoTherapy of Cancer.

Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.

J. Beijnen, G. Sava, B. Nuijen, 2002, Journal of pharmaceutical and biomedical analysis.

Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2007, Rapid communications in mass spectrometry : RCM.

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.

Auke Bult, Jos H Beijnen, J. Beijnen, 2003, Journal of pharmaceutical and biomedical analysis.

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer

J. Beijnen, A. Huitema, J. Schellens, 2006, British Journal of Cancer.

Improving the solubility of nilotinib through novel spray-dried solid dispersions.

J. Schellens, J. Beijnen, B. Nuijen, 2017, International journal of pharmaceutics.

Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry

J. Schellens, H. Rosing, J. Beijnen, 2005, Analytical and bioanalytical chemistry.

A general approach to the interpretation of pH buffer catalyzed degradation profiles

J. Beijnen, A. Bult, O. V. D. Houwen, 1994 .

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of analytical toxicology.

Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2014, Journal of pharmaceutical and biomedical analysis.

A Bead-Based Multiplexed Immunoassay to Evaluate Breast Cancer Biomarkers for Early Detection in Pre-Diagnostic Serum

J. Pennings, P. Peeters, J. Beijnen, 2012, International journal of molecular sciences.

Successful intraperitoneal suramin treatment of peritoneal mesothelioma.

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data

Marcel J. T. Reinders, Lodewyk F. A. Wessels, Wouter Meuleman, 2008, BMC Bioinformatics.

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer

S. Linn, J. Schellens, J. Beijnen, 2018, Clinical Pharmacokinetics.

Slow dissolution behaviour of amorphous capecitabine.

J. Schellens, J. Beijnen, B. Nuijen, 2013, International journal of pharmaceutics.

Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents

J. Beijnen, D. Burger, P. Meenhorst, 1995, Pharmacy World and Science.

Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid

H. Rosing, J. Beijnen, J. Mulder, 1994, Antimicrobial Agents and Chemotherapy.

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

G. Giaccone, C. Punt, J. Beijnen, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma.

J. Schellens, J. Beijnen, J. Prins, 2007, Biomedical chromatography : BMC.

Pharmacokinetic Individualisation of Zidovudine Therapy

J. Beijnen, R. Hoetelmans, D. Burger, 1996, Clinical pharmacokinetics.

Dideoxynucleoside therapy for HIV infection

J. Beijnen, D. Burger, 1992, Pharmaceutisch Weekblad.

Quantitative determination of (-)-2'-deoxy-3'-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Mulder, R. Hoetelmans, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.

H. Rosing, J. Beijnen, O. van Tellingen, 1992, Journal of chromatography.

Pharmacokinetic interaction between rifampin and zidovudine

J. Beijnen, D. Burger, P. Meenhorst, 1993, Antimicrobial Agents and Chemotherapy.

Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug.

J. Beijnen, D. Burger, W. Underberg, 1995, Netherlands Journal of Medicine.

Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde.

J. Schellens, J. Beijnen, R. Sparidans, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics of Zidovudine and Metabolites in a Patient with HIV-Associated Nephropathy and Severe Renal Impairment

J. Beijnen, J. Mulder, A. Bult, 1994 .

steady-state Pharmacokinetics of Twice-daily Dosing of Saquinavir Plus Ritonavir in Hiv-1-infected Individuals

J. Beijnen, J. Lange, J. Mulder, 2001 .

Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.

J. Beijnen, J. Mulder, A. Bult, 1995, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.

Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine.

J. Schellens, J. Beijnen, J. Mulder, 2005, The Journal of infection.

Ritonavir enables combined therapy with rifampin and saquinavir.

J. Beijnen, J. Mulder, R. Hoetelmans, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Pharmacokinetics of Nelfinavir in HIV-1—Infected Children

J. Beijnen, H. Heymans, Linda A de Koning, 2002, Therapeutic drug monitoring.

Limited sampling models for the antiretroviral agent didanosine

J. Beijnen, J. Mulder, A. Bult, 1995 .

Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome.

J. Beijnen, J. Mulder, A. Bult, 1994, Therapeutic Drug Monitoring.

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.

B. Gazzard, J. Montaner, M. Youle, 2001, The Journal of infectious diseases.

Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer

J. Schellens, J. Beijnen, I. Meijerman, 2006, Clinical pharmacokinetics.

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

J. Schellens, J. Beijnen, A. Huitema, 2016, European journal of cancer.

Degradation of mitomycin C in acidic solution

J. Beijnen, W. Underberg, 1985 .

Quantitative aspects of the degradation of mitomycin C in alkaline solution.

J. Beijnen, J. den Hartigh, W. Underberg, 1985, Journal of pharmaceutical and biomedical analysis.

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9

J. Beijnen, A. Bult, R. Henrar, 2004, Investigational New Drugs.

Effect of cyclodextrins on the chemical stability of mitomycins in alkaline solution.

J. Beijnen, A. Bult, O. Bekers, 1991, Journal of pharmaceutical and biomedical analysis.

Degradation kinetics of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) in aqueous solution

J. Beijnen, O. V. D. Houwen, W. Underberg, 1988 .

Qualitative aspects of the degradation of mitomycins in alkaline solution.

J. Beijnen, J. den Hartigh, W. Underberg, 1985, Journal of pharmaceutical and biomedical analysis.

Optimizing drug development of anti‐cancer drugs in children using modelling and simulation

J. Schellens, J. Beijnen, A. Huitema, 2013, British journal of clinical pharmacology.

Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes.

J. Schellens, J. Beijnen, R. Sparidans, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development of farnesyl transferase inhibitors: a review.

J. Schellens, J. Beijnen, N. Appels, 2005, The oncologist.

Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liq

H. Rosing, J. Beijnen, A. Huitema, 2007, Rapid communications in mass spectrometry : RCM.

Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry.

H. Rosing, J. Beijnen, J H Beijnen, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Lange, J. Mulder, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.

H. Rosing, J. Beijnen, A. Huitema, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Jos H. Beijnen, Alfred H. Schinkel, J. Schellens, 2007, Molecular Cancer Therapeutics.

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Mulder, R. Hoetelmans, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Lange, J. Mulder, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Population Pharmacokinetics and Pharmacodynamics of Nelfinavir and Its Active Metabolite M8 in HIV-1-Infected Children

J. Beijnen, T. Kuijpers, A. Huitema, 2006, The Pediatric infectious disease journal.

Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.

J. Beijnen, R. Mathôt, E. V. van Gorp, 2002, Pharmacological research.

Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.

J. Beijnen, E. van de Steeg, A. Schinkel, 2012, Molecular pharmaceutics.

Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

H. Rosing, J. Beijnen, A. Huitema, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

J. Schellens, H. Rosing, J. Beijnen, 2015, Pharmacology research & perspectives.

Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.

J. Beijnen, J. Lange, J. Mulder, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.

J. Wijnholds, R. D. De Abreu, J. Beijnen, 2002, Molecular pharmacology.

Evaluation of two immunoassays for the determination of zidovudine in biological matrices.

J. Beijnen, A. Bult, D. Burger, 1995 .

High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva.

J. Beijnen, J. Mulder, R. Hoetelmans, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Mulder, R. Hoetelmans, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

F. Baas, E. De Clercq, J. Wijnholds, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Simplifying Protease Inhibitor Therapy with Once‐Daily Dosing of Saquinavir Soft‐Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 Study

K. Ruxrungtham, D. Cooper, J. Beijnen, 2002, Journal of acquired immune deficiency syndromes.

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

J. Beijnen, J. Mulder, R. Hoetelmans, 1997, Pharmacy World and Science.

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study

J. Beijnen, J. Lange, J. Mulder, 2000, AIDS.

Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure

J. Beijnen, A. Huitema, E. V. van Gorp, 2008, Antiviral therapy.

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

J. Beijnen, A. Huitema, E. V. van Gorp, 2002, British journal of clinical pharmacology.

Should Non-Nucleoside Reverse Transcriptase Inhibitors be Combined?

J. Beijnen, A. Huitema, B. Kappelhoff, 2005, Drugs in R&D.

The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy

J W Mulder, H. Schuitemaker, J. Beijnen, 1998, AIDS.

Assessing Safety and Efficacy of Directed P-Glycoprotein Inhibition to Improve the Pharmacokinetic Properties of Saquinavir Coadministered with Ritonavir

J. Beijnen, A. Schinkel, M. Huisman, 2003, Journal of Pharmacology and Experimental Therapeutics.

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

J. Beijnen, A. Schinkel, M. Huisman, 2001, Molecular pharmacology.

The Plasma and Intracellular Steady-State Pharmacokinetics of Lopinavir/Ritonavir in HIV-1-Infected Patients

J. Beijnen, A. Huitema, E. V. van Gorp, 2004, Antiviral therapy.

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

Jos H Beijnen, J. Beijnen, A. Schinkel, 2011, Drug Metabolism and Disposition.

Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides

Piet Borst, Jan Wijnholds, J. Wijnholds, 2008, Molecular Cancer Therapeutics.

Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis.

J. Beijnen, M. C. de Waal Malefijt, G. Storm, 2000, Arthritis and rheumatism.

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2013, CNS oncology.

ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2021, Cell reports. Medicine.

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

J. Beijnen, T. Würdinger, M. D. de Gooijer, 2014, Clinical Cancer Research.

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies

A. Berns, J. Beijnen, W. Leenders, 2010, Clinical Cancer Research.

High-grade glioma mouse models and their applicability for preclinical testing.

J. Beijnen, O. van Tellingen, Nienke A. de Vries, 2009, Cancer treatment reviews.

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

A. C. Dubbelman, H. Rosing, J. Beijnen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical experience with aurora kinase inhibitors: a review.

Jos H Beijnen, David S Boss, J. Schellens, 2009, The oncologist.

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

R. Bernards, J. Schellens, H. Rosing, 2020, British Journal of Cancer.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Evert Bosdriesz, Jos H. Beijnen, Ji-Ying Song, 2018, Cell.

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA

J. Schellens, J. Beijnen, D. Pluim, 2013, Investigational New Drugs.

The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry.

Jos H Beijnen, E. J. Rook, H. Rosing, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.

J. Schellens, H. Rosing, J. Beijnen, 2002, European journal of cancer.

High-performance liquid chromatography coupled with mass spectrometry for the quantitative analysis of vinca-alkaloids in biological matrices: a concise survey from the literature.

C. Damen, J. Schellens, H. Rosing, 2010, Biomedical chromatography : BMC.

Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature.

J. Beijnen, O. van Tellingen, W. Nooyen, 1991, Journal of pharmaceutical and biomedical analysis.

P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.

H. Rosing, J. Beijnen, D. de Jong, 2021, Molecular pharmaceutics.

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG21

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2018, Neoplasia.

Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases

J. Schellens, J. Beijnen, K. Sikorska, 2020, Neurology.

The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.

H. Rosing, J. Beijnen, A. Schinkel, 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2

J. Beijnen, D. Sherris, O. Tellingen, 2013, International journal of cancer.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

J. Schellens, H. Rosing, J. Beijnen, 2018, Marine drugs.

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

D. de Jong, J. Schellens, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability.

H. Rosing, J. Beijnen, A. Schinkel, 2019, Molecular pharmaceutics.

Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2005, Investigational New Drugs.

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

J. Schellens, H. Rosing, J. Beijnen, 2005, Investigational new drugs.

ET-743. Commentaries

D. Figgitt, J. Schellens, J. Beijnen, 2002 .

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

Jos H Beijnen, Alwin D R Huitema, S. Rodenhuis, 2008, Pharmacogenetics and genomics.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

J. Schellens, J. Beijnen, K. Heinhuis, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6

J. Schellens, J. Beijnen, L. Sanderson, 2007, Drug metabolism reviews.

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose

H. Rosing, J. Beijnen, A. Huitema, 2020, European Journal of Clinical Pharmacology.

Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D

C. Damen, J. Schellens, H. Rosing, 2009, Analytical and bioanalytical chemistry.

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Jos H Beijnen, Alwin D R Huitema, S. Rodenhuis, 2009, British journal of clinical pharmacology.

Concise drug review: azacitidine and decitabine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2013, The oncologist.

Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites

H. Rosing, J. Beijnen, W. Niessen, 2021 .

Buparlisib is a brain penetrable pan-PI3K inhibitor

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2018, Scientific Reports.

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy

E. Smit, J. Schellens, J. Beijnen, 2012, Cancer.

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

J. Beijnen, A. Schinkel, E. Wagenaar, 2014, International journal of cancer.

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity

J. Schellens, H. Rosing, J. Beijnen, 2017, British Journal of Cancer.

Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel

J. Beijnen, O. van Tellingen, P. Willemse, 1999 .

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

J. Sanderson, U. Amstutz, I. Tomlinson, 2015, The Lancet. Oncology.

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

J. Schellens, J. Beijnen, G. Sonke, 2015, British Journal of Cancer.

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2017, Investigational New Drugs.

Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244)

J. Beijnen, A. Bult, R. Henrar, 1996, Journal of pharmaceutical sciences.

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression

J. Schellens, J. Beijnen, A. Zandvliet, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

J. Schellens, H. Rosing, J. Beijnen, 2013, Cancer Chemotherapy and Pharmacology.

Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2005, Rapid communications in mass spectrometry : RCM.

Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry.

C. Damen, J. Schellens, H. Rosing, 2009, Rapid communications in mass spectrometry : RCM.

Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

S. Rodenhuis, J. Schellens, J. Beijnen, 2000, Clinical pharmacology and therapeutics.

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

S. Rodenhuis, J. Beijnen, E. van der Wall, 1996, British Journal of Cancer.

Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

J. Schellens, J. Beijnen, M. Campone, 2007, Cancer Chemotherapy and Pharmacology.

A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors

J. Schellens, J. Beijnen, S. Howell, 2004, Clinical Cancer Research.

Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.

J. Schellens, J. Beijnen, S. Veltkamp, 2008, The oncologist.

Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.

A. Dahan, J. Beijnen, P. Wielinga, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes

J. Beijnen, A. Huitema, A. Schinkel, 2019, Cancer Chemotherapy and Pharmacology.

Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application

J. Schellens, J. Beijnen, P. Breedveld, 2005, Cancer investigation.

Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium.

H. Rosing, J. Beijnen, M. Tibben, 2020, Journal of pharmaceutical and biomedical analysis.

Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum.

H. Rosing, J. Beijnen, A. Huitema, 2022, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.

Jos H Beijnen, David S Boss, C. Damen, 2009, Analytical biochemistry.

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.

C. Schaefer-Prokop, J. Beijnen, R. ter Heine, 2012, Lung cancer.

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin

J. Schellens, H. Rosing, J. Beijnen, 2008, Analytical and bioanalytical chemistry.

Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium.

J. Schellens, J. Beijnen, J. S. Lagas, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Persistent neuropathy after treatment with cisplatin and oxaliplatin

J. Schellens, J. Beijnen, A. Huitema, 2009, Acta oncologica.

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

Jos H. Beijnen, Alfred H. Schinkel, H. Rosing, 2009, Clinical Cancer Research.

Platinum antitumour agents: A review of (bio)analysis

J. Beijnen, G. Los, W. Underberg, 1992, Pharmaceutisch Weekblad.

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients

J. Schellens, H. Rosing, J. Beijnen, 2022, Drug Metabolism and Disposition.

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

Willem Boogerd, Jos H Beijnen, J. Beijnen, 2004, Cancer treatment reviews.

Does paclitaxel penetrate into brain tumor tissue?

M. Taphoorn, J. Heimans, J. Beijnen, 1995, Journal of the National Cancer Institute.

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

H. Bartelink, J. Beijnen, A. Begg, 1998, European journal of cancer.

A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling.

H. Rosing, J. Beijnen, A. Huitema, 2023, Journal of pharmaceutical and biomedical analysis.

A highly sensitive bioanalytical method for the quantification of vinblastine, vincristine, vinorelbine and 4-O-deacetylvinorelbine in human plasma using LC-MS/MS

H. Rosing, J. Beijnen, L. van Andel, 2022, Journal of Pharmaceutical and Biomedical Analysis.

Degradation kinetics of vinblastine sulphate in aqueous solutions

J. Beijnen, O. V. D. Houwen, D. Vendrig, 1988 .

Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography

J. Beijnen, O. Tellingen, W. Nooijen, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetically Guided Administration of Chemotherapeutic Agents

J. Schellens, J. Beijnen, R. Mathôt, 2000, Clinical pharmacokinetics.

Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens

G. Giaccone, J. Schellens, J. Beijnen, 1998, Clinical drug investigation.

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Ras biochemistry and farnesyl transferase inhibitors: a literature survey

J. Schellens, J. Beijnen, G. Klerk, 2001, Anti-cancer drugs.

Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.

J. Schellens, J. Beijnen, W. S. Siegel-Lakhai, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

J. Beijnen, A. Howes, W. S. Siegel-Lakhai, 2005, British Journal of Cancer.

Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.

Jos H Beijnen, C. Damen, J. Schellens, 2009, Human antibodies.

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

J. Schellens, J. Beijnen, E. Voest, 2011, Clinical Cancer Research.

Improving colorectal cancer management: the potential of proteomics.

J. Schellens, J. Beijnen, A. Cats, 2008, Biomarkers in medicine.

Treatment Individualization in Colorectal Cancer

Jos H. Beijnen, René Bernards, R. Bernards, 2015, Current Colorectal Cancer Reports.

Screening for illicit heroin use in patients in a heroin-assisted treatment program.

E. J. Rook, W. van den Brink, J. Beijnen, 2006, Journal of analytical toxicology.

Deuterodiacetylmorphine as a marker for use of illicit heroin by addicts in a heroin-assisted treatment program.

E. J. Rook, W. van den Brink, J. Beijnen, 2005, Journal of analytical toxicology.

Volatilisation of diacetylmorphine: in vitro simulation of 'chasing the dragon'.

W. van den Brink, J. Beijnen, J. van Ree, 2006, Die Pharmazie.

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Ton N Schumacher, Jos H Beijnen, Wolfgang Uckert, 2014, Human gene therapy methods.

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

J. Beijnen, D. Brandsma, M. V. van Bussel, 2019, BMC Cancer.

Fixed Dosing of Monoclonal Antibodies in Oncology

J. Schellens, J. Beijnen, E. Voest, 2017, The oncologist.

ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2‐Inhibitors

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2015, International journal of cancer.

P‐glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice

J. Beijnen, A. Schinkel, E. Wagenaar, 2017, Pharmacological research.

Breast cancer resistance protein (BCRP/ABCG2) and P‐glycoprotein (P‐gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation☆

J. Beijnen, A. Schinkel, E. Wagenaar, 2017, Pharmacological research.

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

J. Beijnen, A. Schinkel, E. Wagenaar, 2015, Pharmacological research.

“Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183”

J. Schellens, J. Beijnen, D. Pluim, 2014, Investigational New Drugs.

P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib

Jos H Beijnen, J. Beijnen, A. Schinkel, 2012, Journal of Pharmacology and Experimental Therapeutics.

Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

Jos H Beijnen, H. Rosing, J. Beijnen, 2012, International journal of cancer.

Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications

J. Schellens, J. Beijnen, A. Schinkel, 2000, Annals of the New York Academy of Sciences.

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

F H Hausheer, J. Schellens, J. Beijnen, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models

J. Beijnen, T. Würdinger, M. D. de Gooijer, 2016, Clinical Cancer Research.

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

J. Schellens, J. Beijnen, O. Tellingen, 2009, Investigational New Drugs.

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2001, British Journal of Cancer.

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

J. Schellens, H. Rosing, J. Beijnen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts.

J. Beijnen, O. van Tellingen, E. Boven, 1999, European journal of cancer.

The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models

Jos H. Beijnen, Piet Borst, Gerrit Jansen, 2007, Molecular Pharmacology.

Pharmaceutical heroin for inhalation: thermal analysis and recovery experiments after volatilisation.

J. Beijnen, B. Nuijen, J. van Ree, 2005, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetic comparison of two methods of heroin smoking: ‘chasing the dragon’ versus the use of a heating device

E. J. Rook, J. M. Ree, J. Beijnen, 2005, European Neuropsychopharmacology.

Development and Manufacture of Diacetylmorphine/Caffeine Sachets for Inhalation Via ‘Chasing the Dragon’ by Heroin Addicts

W. van den Brink, J. Beijnen, B. Nuijen, 2004, Drug development and industrial pharmacy.

The effect of complementary and alternative medicines on CYP3A4‐mediated metabolism of three different substrates: 7‐benzyloxy‐4‐trifluoromethyl‐coumarin, midazolam and docetaxel

J. Schellens, H. Rosing, J. Beijnen, 2014, The Journal of pharmacy and pharmacology.

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

J. Schellens, J. Beijnen, O. van Tellingen, 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.

J. Schellens, J. Beijnen, A. de Boer, 2017, The oncologist.

Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

S. Linn, J. Schellens, J. Beijnen, 2015, Clinical breast cancer.

Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes

J. Schellens, J. Beijnen, B. Nuijen, 2001, Investigational New Drugs.

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

J. Beijnen, A. Sparreboom, O. van Tellingen, 1996, Cancer research.

Tissue distribution, metabolism and excretion of paclitaxel in mice

J. Beijnen, A. Sparreboom, O. van Tellingen, 1996, Anti-cancer drugs.

An overview of the clinical pharmacology of topotecan.

L. Grochow, J. Beijnen, M. Dennis, 1997, Seminars in oncology.

Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population

J. Schellens, J. Beijnen, I. Meijerman, 2012, Molecular Diagnosis & Therapy.

Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer

H. Rosing, J. Beijnen, A. Huitema, 2019, Prostate Cancer and Prostatic Diseases.

Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

W. M. Smit, J. Schellens, J. Beijnen, 2006, Clinical Cancer Research.

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.

J. Schellens, J. Beijnen, A. Goey, 2013, Cancer treatment reviews.

Abcc 4 together with Abcb 1 and Abcg 2 form a robust co-operative drug efflux system that restricts the brain entry of camptothecin analogs

J. Beijnen, D. Pluim, R. Mazzanti, 2013 .

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

J. Schellens, H. Rosing, J. Beijnen, 2012, Bioanalysis.

A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling

J. Schellens, J. Beijnen, H. J. van den Bongard, 2002, Cancer Chemotherapy and Pharmacology.

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction

J. Schellens, J. Beijnen, H. Boot, 2015, Cancer Chemotherapy and Pharmacology.

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

J. Schellens, J. Beijnen, H. Boot, 2013, International journal of radiation oncology, biology, physics.

Oral Delivery of Taxanes

J. Schellens, J. Beijnen, M. Malingré, 2001, Investigational New Drugs.

The risks of handling cytotoxic drugs

J. Beijnen, W. Underberg, G. Kaijser, 1990, Pharmaceutisch Weekblad.

Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients

J. Beijnen, P. D. de Vries, A. Huitema, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials

J. Beijnen, S. Marchetti, Marit A. C. Vermunt, 2021, Clinical pharmacology : advances and applications.

CPAA_A_292746 21..32

J. Beijnen, S. Marchetti, Marit A. C. Vermunt, 2021 .

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

J. Schellens, J. Beijnen, A. Huitema, 2014, Clinical Pharmacokinetics.

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs

J. Beijnen, A. Huitema, N. Steeghs, 2021, Frontiers in Pharmacology.

Degradation kinetics of the antitumour drug nimustine (ACNU) in aqueous solution

J. Beijnen, A. Bult, O. Bekers, 1993 .

Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin.

E. J. Rook, W. van den Brink, J. Beijnen, 2006, Drug and alcohol dependence.

The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review.

W. van den Brink, J. Beijnen, A. Uchtenhagen, 2021, Drug and alcohol dependence.

Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein

Jos H. Beijnen, Piet Borst, Jan Wijnholds, 1997, Nature Medicine.

P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.

J. Schellens, J. Beijnen, J H Beijnen, 1999, Pharmacological research.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Cancer treatment reviews.

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

J. Schellens, J. Beijnen, D. de Jong, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.

J. Schellens, J. Beijnen, I. Meijerman, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

Willem Boogerd, Jos H Beijnen, J. Beijnen, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK

A. Heck, J. Beijnen, D. Peeper, 2015, Pigment cell & melanoma research.

Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.

J. Schellens, J. Beijnen, S. Leijen, 2013, Cancer treatment reviews.

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

J. Schellens, J. Beijnen, J. Haanen, 2013, Cancer treatment reviews.

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

J. Schellens, J. Beijnen, R. Mathijssen, 2015, British journal of clinical pharmacology.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

S. Sleijfer, J. Schellens, J. Beijnen, 2014, British Journal of Cancer.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome

J. Schellens, J. Beijnen, C. Blank, 2013, European Journal of Clinical Pharmacology.

Quantification of Sunitinib and N-Desethyl Sunitinib in Human EDTA Plasma by Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry: Validation and Application in Routine Therapeutic Drug Monitoring

J. Schellens, H. Rosing, J. Beijnen, 2013, Therapeutic drug monitoring.

Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer.

J. Schellens, J. Beijnen, I. Meijerman, 2008, Cancer treatment reviews.

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel

J. Schellens, J. Beijnen, L. V. van Warmerdam, 1999, Journal of Cancer Research and Clinical Oncology.

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

S. Rodenhuis, H. Rosing, J. Beijnen, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

J. Beijnen, A. Schinkel, R. Sparidans, 2022, Pharmacological research.

Gas chromatographic analysis, with nitrogen detection, of tocainide in plasma.

J. Beijnen, W. Underberg, R. van Gijn, 1990, Journal of pharmaceutical and biomedical analysis.

A Phase 1 Dose‐Escalation Study of Low‐Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors

H. Rosing, J. Beijnen, A. Huitema, 2020, Clinical pharmacology in drug development.

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

J. Schellens, H. Rosing, J. Beijnen, 2020, Pharmaceutical Research.

Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.

R. Bernards, J. Schellens, H. Rosing, 2020, Future oncology.

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

J. Schellens, J. Beijnen, Jin Zhao, 2012, Investigational New Drugs.

A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2001, Journal of Pharmacokinetics and Pharmacodynamics.

Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).

S. Rodenhuis, H. Rosing, J. Beijnen, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE STABILIZED CYCLOPHOSPHAMIDE METABOLITE 4-HYDROXYCYCLOPHOSPHAMIDE IN PLASMA AND RED BLOOD CELLS

S. Rodenhuis, J. Beijnen, A. Huitema, 2000 .

Pharmacokinetics of Cyclophosphamide and Thiotepa in a Conventional Fractionated High-Dose Regimen Compared With a Novel Simplified Unfractionated Regimen

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Therapeutic drug monitoring.

Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

S. Rodenhuis, H. Rosing, J. Beijnen, 2004, Journal of mass spectrometry : JMS.

High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes.

H. Keizer, J. Beijnen, A. Huitema, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2001, Anti-cancer drugs.

The degradation of N,N',N"-triethylenephosphoramide in aqueous solutions: a qualitative and kinetic study.

J. Beijnen, J. W. Zwikker, J. M. Damen, 2000, International journal of pharmaceutics.

A search for new metabolites of N,N',N''-triethylenethiophosphoramide.

S. Rodenhuis, A. Heck, J. Beijnen, 1999, Cancer research.

Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.

S. Rodenhuis, J. Beijnen, J. W. Zwikker, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Validation of a Therapeutic Drug Monitoring Strategy for Thiotepa in a High-Dose Chemotherapy Regimen

S. Rodenhuis, J. Beijnen, A. Huitema, 2001, Therapeutic drug monitoring.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Reasons for Undertreatment with Oral Anticoagulants in Frail Geriatric Outpatients with Atrial Fibrillation

J. Beijnen, H. Tinteren, L. Tulner, 2010, Drugs & aging.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

J. Schellens, J. Beijnen, A. Huitema, 2011, International journal of pharmaceutics.

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor

J. H. Beijnen, J. Schellens, J. Beijnen, 2009, Cancer Chemotherapy and Pharmacology.

Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein

Piet Borst, J. Beijnen, P. Borst, 1996, British journal of pharmacology.

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

R. Bernards, J. Schellens, H. Rosing, 2020, Cancer Chemotherapy and Pharmacology.

Allometric scaling of pegylated liposomal anticancer drugs

J. Schellens, J. Beijnen, H. Clewell, 2011, Journal of Pharmacokinetics and Pharmacodynamics.

Acquired and intrinsic resistance to vemurafenib in BRAFV600E-driven melanoma brain metastases

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2022, bioRxiv.

Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients.

H. Rosing, J. Beijnen, C. Zwaan, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Milk Thistle’s Active Components Silybin and Isosilybin: Novel Inhibitors of PXR-Mediated CYP3A4 Induction

J. Schellens, J. Beijnen, I. Meijerman, 2013, Drug Metabolism and Disposition.

Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.

H. Rosing, J. Beijnen, B. van Hoek, 2019, Clinical genitourinary cancer.

Impact of age on exposure to oral antiandrogen therapies in clinical practice

J. Schellens, H. Rosing, J. Beijnen, 2018, Prostate Cancer and Prostatic Diseases.

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

J. Wanders, J. Schellens, J. Beijnen, 2012, British Journal of Cancer.

ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.

H. Rosing, J. Beijnen, M. Tibben, 2021, Pharmacological research.

OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation

J. Beijnen, A. Schinkel, R. Sparidans, 2020, British journal of pharmacology.

P‐glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability

J. Beijnen, A. Schinkel, R. Sparidans, 2018, Pharmacological research.

The biological and clinical role of drug transporters at the intestinal barrier.

Jos H Beijnen, J. Schellens, J. Beijnen, 2009, Cancer treatment reviews.

P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin

Jos H. Beijnen, Alfred H. Schinkel, J. Beijnen, 2007, Antimicrobial Agents and Chemotherapy.

Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice

J. Schellens, H. Rosing, J. Beijnen, 2006, Journal of Pharmacology and Experimental Therapeutics.

Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of pharmaceutical and biomedical analysis.

The pharmacokinetics of reduced folates after intraperltoneal and intravenous administration of racemic [6S,R]-folinic acid

S. Rodenhuis, J. Beijnen, O. Tellingen, 2004, Cancer Chemotherapy and Pharmacology.

Bioanalysis of the investigational anti-tumour drug 5,10-dideaza-5,6,7,8-tetrahydrofolic acid by high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Schornagel, O. van Tellingen, 1992, Journal of chromatography.

Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides

J. Beijnen, P. Borst, N. Zelcer, 2007, Molecular Pharmacology.

Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.

S. Sleijfer, D. Richel, J. Schellens, 2012, European urology.

Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Bioanalytical method for the simultaneous quantification of irinotecan and its active metabolite SN-38 in mouse plasma and tissue homogenates using HPLC-fluorescence.

H. Rosing, J. Beijnen, A. Schinkel, 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The use of combinations of monoclonal antibodies in clinical oncology.

J. Schellens, J. Beijnen, A. Huitema, 2015, Cancer treatment reviews.

Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas

A. C. Dubbelman, J. Schellens, H. Rosing, 2015, Investigational New Drugs.

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

R. Boellaard, J. Beijnen, D. Peeper, 2017, BMC Cancer.

Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics of ifosfamide and some metabolites in children.

J. Beijnen, A. Bult, J. de Kraker, 1998, Anticancer research.

Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer

J. Schellens, H. Rosing, J. Beijnen, 2004, Clinical Cancer Research.

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

J. Schellens, J. Beijnen, W. S. Siegel-Lakhai, 2005, The oncologist.

Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites

H. Groen, H. Keizer, J. Schellens, 2001, Clinical Pharmacokinetics.

Clinical proteomics in breast cancer: a review

Jos H. Beijnen, Marie-Christine W. Gast, J. Schellens, 2009, Breast Cancer Research and Treatment.

Therapeutic drug monitoring in cancer--are we missing a trick?

Nicolas Widmer, Alain Astier, Christophe Bardin, 2014, European journal of cancer.

Population pharmacokinetic modelling to support the evaluation of preclinical pharmacokinetic experiments with lorlatinib.

J. Beijnen, A. Huitema, A. Schinkel, 2021, Journal of pharmaceutical sciences.

High Performance Liquid Chromatographic Analysis of The Cardioprotective Agent Dexrazoxane in Human Plasma and Urine

H. Rosing, J. Beijnen, R. Gijn, 1997 .

Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study

J. Schellens, H. Rosing, J. Beijnen, 2012, Cancer Chemotherapy and Pharmacology.

Extrahepatic metabolism of ibrutinib

J. Beijnen, A. Schinkel, R. Masereeuw, 2020, Investigational New Drugs.

Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate.

J. Beijnen, S. Cremers, J. den Hartigh, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

S. Rodenhuis, E. Barillot, A. Nicolas, 2020, British Journal of Cancer.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice

P. V. van Diest, H. Rosing, J. Beijnen, 2017, Oncotarget.

Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin

H. Lipp, C. Bokemeyer, J. Beijnen, 2011, Cancer Chemotherapy and Pharmacology.

Lapatinib for advanced or metastatic breast cancer.

Henk-Jan Guchelaar, Jos H Beijnen, J. Schellens, 2012, The oncologist.

Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors.

D. Richel, J. Schellens, J. Beijnen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic biomarkers in model-based drug development in oncology.

J. Schellens, J. Beijnen, A. Huitema, 2011, Current clinical pharmacology.

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

J. Beijnen, J. Klaase, B. Kroon, 1994, British Journal of Cancer.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

J. Schellens, J. Beijnen, G. Groenewegen, 2002, Cancer Chemotherapy and Pharmacology.

Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver

R. Tollenaar, H. Keizer, J. H. van Bockel, 2000, British Journal of Cancer.

Reduced Liver Uptake of Arterially Infused Melphalan during Retrograde Rat Liver Perfusion with Unaffected Liver Tumor Uptake

H. Putter, C. V. D. van de Velde, J. Beijnen, 2002, Journal of Pharmacology and Experimental Therapeutics.

Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue.

J. Schellens, J. Beijnen, G. Mulder, 2003, Biomedical chromatography : BMC.

Population Pharmacokinetics and Pharmacodynamics of Mitomycin During Intraoperative Hyperthermic Intraperitoneal Chemotherapy

J. Beijnen, F. Zoetmulder, R. Mathôt, 2004, Clinical pharmacokinetics.

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.

R. Bernards, J. Beijnen, N. Steeghs, 2020, Future oncology.

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53

J. Beijnen, M. V. van Velthuysen, J. Schellens, 2015, British Journal of Cancer.

Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine.

A. C. Dubbelman, J. Schellens, H. Rosing, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.

J. Schellens, J. Beijnen, L. V. Valkenburg-van Iersel, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics

H. Rosing, J. Beijnen, O. van Tellingen, 2006, Clinical Cancer Research.

Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study

H. Rosing, J. Beijnen, E. Sanidas, 2008, Annals of Surgical Oncology.

Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.

H. Rosing, J. Beijnen, D. Tsiftsis, 2006, Cancer treatment reviews.

Mitoxantrone extravasation injury.

J. Beijnen, W. W. ten Bokkel Huinink, F. T. Peters, 1987, Cancer treatment reports.

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule

J. Schellens, H. Rosing, J. Beijnen, 2002, Cancer Chemotherapy and Pharmacology.

Stability of anthracycline antitumour agents in infusion fluids.

H. Rosing, J. Beijnen, P. de Vries, 1985, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.

J. Beijnen, A. Schinkel, R. Sparidans, 2019, International journal of pharmaceutics.

Compatibility and Stability of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F in Infusion Devices

J. Beijnen, J. Jimeno, B. Nuijen, 2004, Investigational new drugs.

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2009, Clinical Cancer Research.

Oral topotecan: bioavailability and effect of food co-administration

J. Schellens, H. Rosing, J. Beijnen, 1999, British Journal of Cancer.

Analysis of diacetylmorphine, caffeine, and degradation products after volatilization of pharmaceutical heroin for inhalation.

W. van den Brink, J. Beijnen, M. Hillebrand, 2006, Journal of analytical toxicology.

Differential impact of impaired fasting glucose versus impaired glucose tolerance on cardiometabolic risk factors in multi-ethnic overweight/obese children

J. Beijnen, J. Rotteveel, M. Diamant, 2010, European Journal of Pediatrics.

The Effects of Fall-Risk-Increasing Drugs on Postural Control: A Literature Review

C. Lamoth, J. Beijnen, L. Tulner, 2013, Drugs & Aging.

Bioavailability andpharmacokinetics oforal topotecan: a new topoisomerase Iinhibitor

H. Rosing, J. Beijnen, M. Boer-Dennert, 1996 .

Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

J. Beijnen, A. Schinkel, R. Sparidans, 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Synthetic vehicles for DNA vaccination

T. Schumacher, J. Beijnen, W. Hennink, 2009, Journal of drug targeting.

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

J. Beijnen, B. Nuijen, A. Bult, 1999, Anti-cancer drugs.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

G. Giaccone, J. Schellens, J. Beijnen, 2000, Anti-cancer drugs.

EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors.

J. Westerga, J. Schellens, J. Beijnen, 2016, Neuro-oncology.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid

J. Schellens, J. Beijnen, D. Pluim, 2018, Journal of Neuro-Oncology.

Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.

J. Schellens, J. Beijnen, R. Mathôt, 2002, Pharmacology & toxicology.

Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report

D. de Jong, J. Wanders, J. Schellens, 2011 .

HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial

T. Schumacher, G. Kenter, J. Beijnen, 2021, Journal for ImmunoTherapy of Cancer.

GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.

T. Schumacher, J. Beijnen, J. Haanen, 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.

H. Keizer, J. Schellens, J. Beijnen, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2005, Clinical pharmacokinetics.

Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method.

D. Scherman, J. Beijnen, R. de Boer, 2019, Journal of Biotechnology.

Predictive Value of Microdose Pharmacokinetics

Jos H. Beijnen, Alwin D. R. Huitema, H. Rosing, 2019, Clinical Pharmacokinetics.

Acute poisoning after oral intake of a toluene-containing paint thinner

J. Schellens, J. Beijnen, M. Tibben, 2002, European Journal of Pediatrics.

Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboﬂavin (Vitamin B 2 ) into Milk (cid:1)

H. Rosing, J. Beijnen, A. Schinkel, 2007 .

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

J. Schellens, J. Beijnen, J. Schornagel, 2006, British journal of clinical pharmacology.

Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis

J. Beijnen, P. D. de Vries, A. Huitema, 2012, Antimicrobial Agents and Chemotherapy.

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection

J. Schellens, H. Rosing, J. Beijnen, 2016, Antimicrobial Agents and Chemotherapy.

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.

H. Rosing, J. Beijnen, P. D. de Vries, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.

H. Rosing, J. Beijnen, T. Dorlo, 2022, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Urinary excretion of paclitaxel and metabolites in a large series study

H. Rosing, J. Beijnen, L. V. van Warmerdam, 1998 .

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours

J. Schellens, H. Rosing, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

The preparation of radiolabeled monoclonal antibodies for human use.

J. Beijnen, A. Huitema, L. Tran, 2009, Human antibodies.

Intermittent fasting during Ramadan causes a transient increase in total, LDL, and HDL cholesterols and hs-CRP in ethnic obese adolescents

M. Heymans, J. Beijnen, M. Diamant, 2014, European Journal of Pediatrics.

Limited Sampling Strategies for Investigating Paclitaxel Pharmacokinetics in Patients Receiving 175 mg/m2 as a 3-Hour Infusion

H. Rosing, J. Beijnen, H. Pinedo, 1995 .

Cyclosporine-Induced Anaphylaxis

J. Schellens, J. Beijnen, R. A. Kuiper, 2000, The Annals of pharmacotherapy.

Pharmacokinetics and Excretion of 14C-Bendamustine in Patients with Relapsed or Refractory Malignancy

A. C. Dubbelman, J. Schellens, H. Rosing, 2013, Drugs in R&D.

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

J. Schellens, J. Beijnen, B. Thürlimann, 2016, Cancers.

In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.

J. Schellens, J. Beijnen, J. D. J. van den Berg, 1998, Cancer treatment reviews.

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites

J. Beijnen, A. Schinkel, Wenlong Li, 2022, Frontiers in Pharmacology.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

J. Beijnen, J. Schornagel, W. W. ten Bokkel Huinink, 2006, British Journal of Cancer.

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study

M. Piccart, J. Beijnen, L. Schaaf, 1998, Cancer Chemotherapy and Pharmacology.

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

S. Rodenhuis, H. Rosing, J. Beijnen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration

J. Schellens, H. Rosing, J. Beijnen, 2000, Anti-cancer drugs.

A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application

J. Schellens, H. Rosing, J. Beijnen, 2006, Cancer Chemotherapy and Pharmacology.

The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa.

J. Beijnen, A. Huitema, G. Kaspers, 2023, Therapeutic drug monitoring.

the assessment of duration of contraceptive use after

J. Beijnen, M. Balasegaram, M. A. Lima, 2012 .

Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.

H. Rosing, J. Beijnen, T. Dorlo, 2021, Journal of pharmaceutical and biomedical analysis.

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa

J. Beijnen, J. Mbui, T. Dorlo, 2020, The Journal of antimicrobial chemotherapy.

Characterization and identification of suspected counterfeit miltefosine capsules.

J. Beijnen, P. D. de Vries, T. Dorlo, 2012, The Analyst.

Metabolite Profiling of Bendamustine in Urine of Cancer Patients after Administration of [14C]Bendamustine

A. C. Dubbelman, J. Schellens, H. Rosing, 2012, Drug Metabolism and Disposition.

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study

J. Schellens, J. Beijnen, K. Sikorska, 2016, Investigational New Drugs.

A multi-gram-scale stereoselective synthesis of Z-endoxifen.

J. Beijnen, L. Brunsveld, L. Milroy, 2018, Bioorganic & medicinal chemistry letters.

Long term stability of lyophilized plasmid DNA pDERMATT.

Jos H Beijnen, J. Beijnen, B. Nuijen, 2013, International journal of pharmaceutics.

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

W. M. Smit, J. Schellens, H. Rosing, 2015, Investigational New Drugs.

Baclofen overdose treated with continuous venovenous hemofiltration

J. Schellens, J. Beijnen, A. Huitema, 2015, European Journal of Clinical Pharmacology.

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

J. Schellens, J. Beijnen, E. Voest, 2007, Clinical Cancer Research.

Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

Diederick E Grobbee, Marie-Christine W. Gast, Jos H Beijnen, 2011, BMC Cancer.

Discontinuation of rivastigmine in routine clinical practice

J. Beijnen, B. Appels, L. Tulner, 2005, International journal of geriatric psychiatry.

Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.

W. van den Brink, J. Beijnen, A. Zandvliet, 2005, Basic & clinical pharmacology & toxicology.

Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.

Marie-Christine W. Gast, P. Span, J. Schellens, 2011, Journal of cancer research and clinical oncology.

Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients

Marie-Christine W. Gast, S. Rodenhuis, P. Span, 2008, BMC Cancer.

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical pharmacology.

Identification of the degradation products of gonadorelin and three analogues in aqueous solution

J. Beijnen, A. Bult, W. Underberg, 1997 .

Influence of variations in sample handling on SELDI‐TOF MS serum protein profiles for colorectal cancer

J. Schellens, J. Beijnen, A. Cats, 2008, Proteomics. Clinical applications.

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Jos H Beijnen, J. Schellens, J. Beijnen, 2006, World journal of gastroenterology.

Validation of a quantitative assay for human neutrophil peptide-1, -2, and -3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry.

J. Schellens, J. Beijnen, R. Sparidans, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.

J. Schellens, H. Rosing, J. Beijnen, 2006, Journal of mass spectrometry : JMS.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

S. Sleijfer, J. Schellens, J. Beijnen, 2010, Annals of Oncology.

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Pharmacokinetic variability of zidovudine in HIV‐infected individuals: subgroup analysis and drug interactions

J. Beijnen, J. Mulder, D. Burger, 1994, AIDS.

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations

J. Schellens, J. Beijnen, E. Voest, 2007, Laboratory Investigation.

High-performance liquid chromatographic method for the analysis of 10-ethyl-10-deaza-aminopterin and metabolites in plasma.

J. Beijnen, O. van Tellingen, P. Bruning, 1990, Journal of chromatography.

Identification of two new serum protein profiles for renal cell carcinoma.

J. Schellens, J. Beijnen, E. Voest, 2009, Oncology reports.

Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS)

Marie-Christine W. Gast, E. Rutgers, J. Schellens, 2009, Clinical chemistry and laboratory medicine.

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen

S. Linn, J. Schellens, H. Rosing, 2012, Breast Cancer Research and Treatment.

Signal transduction pathways: New targets in oncology

J. Beijnen, R. K. Sweeb, J. H. Beijnen, 1993, Pharmacy World and Science.

Development and validation of a high‐performance liquid chromatography‐tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma

J. Schellens, H. Rosing, J. Beijnen, 2018, Journal of pharmaceutical and biomedical analysis.

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).

J. Beijnen, A. Schinkel, E. Wagenaar, 2019, Pharmacological research.

Abstracts of papers and posters Meeting on Pharmaceutical Sciences

S. W. F. Omta, Gert Luurtsema, John Urquhart, 1993, Pharmacy World and Science.

Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer

J. Schellens, J. Beijnen, A. Huitema, 2012, Journal of palliative care.

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

J. Beijnen, A. Huitema, E. van Werkhoven, 2022, BMC Cancer.

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology

J. Schellens, J. Beijnen, A. Huitema, 2018, Clinical Pharmacokinetics.

Early diagnostic protein biomarkers for breast cancer: how far have we come?

R. Vermeulen, P. Peeters, J. Beijnen, 2012, Breast Cancer Research and Treatment.

Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.

A. C. Dubbelman, J. Beijnen, W. Underberg, 1991, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials.

J. Beijnen, P. Baas, J. Haanen, 2020, Journal of Geriatric Oncology.

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

J. Schellens, J. Beijnen, R. Sparidans, 2010, Clinical Proteomics.

Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling.

Marie-Christine W. Gast, J. Westerga, J. Schellens, 2009, The International journal of biological markers.

Detection of Breast Cancer by Surface-enhanced Laser Desorption/Ionization Time-of-flight Mass Spectrometry Tissue and Serum Protein Profiling

Marie-Christine W. Gast, J. Westerga, J. Schellens, 2009 .

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

J. Schellens, J. Beijnen, K. Sikorska, 2016, The Pharmacogenomics Journal.

Proteomics in uveal melanoma

J. Keunen, J. Beijnen, J. Bonfrer, 2003, Melanoma research.

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

J. Schellens, J. Beijnen, A. Huitema, 2014, Therapeutic drug monitoring.

The absolute quantification of eight inter‐α‐trypsin inhibitor heavy chain 4 (ITIH4)‐derived peptides in serum from breast cancer patients

Marie-Christine W. Gast, J. Schellens, J. Beijnen, 2010, Proteomics. Clinical applications.

Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study

D. Grobbee, P. Peeters, J. Beijnen, 2009, BMC Medical Genomics.

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

J. Schellens, J. Beijnen, A. Huitema, 2021, Cancer Chemotherapy and Pharmacology.

LC–MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide

H. Rosing, J. Beijnen, H. V. van Rossum, 2019, Journal of pharmaceutical and biomedical analysis.

New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

Jos H. Beijnen, Jashvant D. Unadkat, J. Schellens, 2008, Molecular Cancer Therapeutics.

Derivatization of pamidronate and other amino(bis)phosphonates with different isothiocyanates prior to ion-pair liquid chromatography

J. Beijnen, J. Hartigh, R. Sparidans, 1997 .

Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry.

J. Schellens, J. Beijnen, R. Sparidans, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.

H. Rosing, J. Beijnen, D. Tsiftsis, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A dose-dependent delayed hypersensitivity reaction to acetaminophen after repeated acetaminophen intoxications

J. Beijnen, J. Beijnen, P. Meenhorst, 1998, Human & experimental toxicology.

Suppression of migration inhibition factor (MIF) production by mitomycins in vitro.

J. Beijnen, W. Underberg, H. van Dijk, 1986, Immunobiology.

Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg(6), D-Trp(7,9), MePhe(8)] substance P[6-11].

J. Beijnen, A. Bult, W. Underberg, 1999, Journal of pharmaceutical and biomedical analysis.

Kinetics and mechanism of the degradation of la-acetylmitomycin C in aqueous solution

J. Beijnen, W. Underberg, 1993, Pharmacy World and Science.

A systematic study on the chemical stability of mitomycin A and mitomycin B.

H. Rosing, J. Beijnen, W. Underberg, 1986, Chemical and pharmaceutical bulletin.

Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry

J. Schellens, J. Beijnen, A. Huitema, 2007, International archives of occupational and environmental health.

Abstracts of Dutch doctoral theses

J. Beijnen, 2005, Pharmaceutisch Weekblad.

Stabilization of mitomycins on complexation with cyclodextrins in aqueous acidic media

J. Beijnen, M. Otagiri, A. Bult, 1989 .

The Effect of Cyclodextrins on the Mitomycin Stability in Acidic Aqueous Media

J. Beijnen, O. Bekers, W. Underberg, 1988 .

Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies

J. Schellens, J. Beijnen, B. Nuijen, 2017, Drug development and industrial pharmacy.

[Pleurodesis in malignant pleural effusion].

J. Beijnen, P. Baas, G. M. Bronner, 1997, Nederlands tijdschrift voor geneeskunde.

High prevalence of vitamin D insufficiency/deficiency in Dutch multi-ethnic obese children

J. Beijnen, M. Diamant, D. Brandjes, 2015, European Journal of Pediatrics.

Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters

J. Beijnen, A. Schinkel, E. Wagenaar, 2010, Molecular Pharmacology.

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration‐resistant Prostate Cancer Undergoing Hemodialysis

H. Rosing, J. Beijnen, A. Huitema, 2019, Clinical genitourinary cancer.

Impact of age on exposure to oral antiandrogen therapies in clinical practice

J. Schellens, H. Rosing, J. Beijnen, 2018, Prostate Cancer and Prostatic Diseases.

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment

J. H. Beijnen, A. D. R. Huitema, J. Beijnen, 2016, European Journal of Clinical Pharmacology.

Cardiometabolic risk variables in overweight and obese children: a worldwide comparison

M. Heymans, J. Beijnen, M. Diamant, 2011, Cardiovascular diabetology.

The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.

J. Schellens, H. Rosing, J. Beijnen, 2013, British journal of clinical pharmacology.

Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate.

J. Beijnen, J. Hartigh, J. den Hartigh, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Gas chromatographic determination of ifosfamide in microvolumes of urine and plasma.

J. Beijnen, A. Bult, J. de Kraker, 1991, Journal of chromatography.

In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug

J. Schellens, J. Beijnen, E. Brandon, 2007, Investigational New Drugs.

Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [ Arg 6 , D-Trp 7 , 9 , MePhe 8 ]-Substance P { 6-11 }

H. Rosing, J. Beijnen, H. Talsma, 1998 .

Pharmacotherapy of Hospitalised HIV-Infected Patients in a General Hospital during 1990, 1997 and 2001

T. Post, J. Beijnen, D. Jonker, 2003, Clinical drug investigation.

Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors.

H. Rosing, J. Beijnen, L. Lucas, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

evelopment and validation of a high-performance liquid hromatography – tandem mass spectrometry assay quantifying laparib in human plasma

J. Schellens, H. Rosing, J. Beijnen, 2013 .

Model-based treatment optimization of a novel VEGFR inhibitor.

J. Schellens, J. Beijnen, A. Huitema, 2012, British journal of clinical pharmacology.

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients

E. Smit, H. Rosing, J. Beijnen, 2020, Clinical pharmacology and therapeutics.

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.

O. Dalesio, J. Schellens, J. Beijnen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follow up survey for implementation of fixed-dosing of monoclonal antibodies

J. Beijnen, K. Heinhuis, J. Hendrikx, 2020, International Journal of Clinical Pharmacy.

Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS).

J. Beijnen, L. Tulner, S. V. Frankfort, 2008, Current clinical pharmacology.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Jos H Beijnen, J. Beijnen, M. Verbeek, 2008, Current clinical pharmacology.

ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients

J. Beijnen, P. Smits, L. Tulner, 2006, Molecular Neurodegeneration.

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option

J. Schellens, J. Beijnen, J. Schellens, 2014, British Journal of Cancer.

Degradation kinetics of etoposide in aqueous solution

J. Beijnen, A. Bult, O. V. D. Houwen, 1988 .

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study

J. Schellens, J. Beijnen, K. Sikorska, 2016, Cancer.

Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.

J. Beijnen, H. Talsma, G. Sava, 2002, International journal of pharmaceutics.

Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle

J. Beijnen, D. Mirejovsky, F. Flesch, 2007, AAPS PharmSciTech.

Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel.

J. Schellens, J. Beijnen, B. Nuijen, 2016, International journal of pharmaceutics.

Complexation Study of the Anticancer Agent EO-9 with 2-hydroxypropyl-β-Cyclodextrin

J. Beijnen, D. Mirejovsky, F. Flesch, 2008 .

Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9

J. Beijnen, H. Talsma, A. Bult, 2004, Cancer Chemotherapy and Pharmacology.

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.

A. Heck, J. Beijnen, H. Talsma, 2000, PDA journal of pharmaceutical science and technology.

Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.

J. Beijnen, A. Schinkel, M. Lebre, 2023, Molecular pharmaceutics.

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies

J. Beijnen, A. Huitema, T. Dorlo, 2022, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

J. Schellens, J. Beijnen, A. Huitema, 2010, British journal of clinical pharmacology.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet

J. Schellens, J. Beijnen, A. Huitema, 2013, Drug Delivery and Translational Research.

EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studies.

J. Beijnen, D. Mirejovsky, B. Nuijen, 2007, International journal of pharmaceutics.

Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent.

J. Beijnen, C. Lutz, B. Nuijen, 2005, Journal of pharmaceutical sciences.

Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.

J. Verweij, J. Beijnen, W. Loos, 1993, Journal of chromatography.

EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs.

J. Beijnen, J. Davignon, J. Slack, 1988, European journal of cancer & clinical oncology.

DEVELOPMENT OF AN HPLC METHOD WITH UV DETECTION FOR THE PHARMACEUTICAL QUALITY CONTROL OF THE NOVEL MARINE ANTICANCER AGENT KAHALALIDE F

H. Rosing, J. Beijnen, E. Stokvis, 2001 .

HPLC-UV METHOD DEVELOPMENT AND IMPURITY PROFILING OF THE MARINE ANTICANCER AGENT APLIDINE IN RAW DRUG SUBSTANCE AND PHARMACEUTICAL DOSAGE FORM

J. Beijnen, B. Nuijen, A. Bult, 2001 .

Development of a Lyophilized Parenteral Pharmaceutical Formulation of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F

J. Beijnen, H. Talsma, J. Jimeno, 2001, Drug development and industrial pharmacy.

Analysis of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and Its Phase I and Phase II Metabolites in Mouse Urine Using LC–UV–MS–MS

J. Schellens, H. Rosing, J. Beijnen, 2011 .

Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors

J. Beijnen, A. Huitema, Maarten van Eijk, 2022, Anti-cancer drugs.

Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison

A. C. Dubbelman, J. Schellens, H. Rosing, 2016, Investigational New Drugs.

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

J. Schellens, J. Beijnen, M. Karlsson, 2009, Investigational New Drugs.

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

J. Wanders, J. Schellens, J. Beijnen, 2008, British journal of clinical pharmacology.

A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam

J. Schellens, J. Beijnen, A. Zandvliet, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies

J. Wanders, E. Raymond, J. Schellens, 2002 .

Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study

G. Meijer, I. Lansdorp-Vogelaar, J. Beijnen, 2021, BMC Gastroenterology.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

J. Wanders, J. Beijnen, J. Smyth, 2003, European journal of cancer.

Serum degradome markers for the detection of breast cancer.

Marie-Christine W. Gast, P. Peeters, J. Schellens, 2010, Journal of proteome research.

Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects.

J. Schellens, H. Rosing, J. Beijnen, 2014, Bioanalysis.

Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of pharmaceutical and biomedical analysis.

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?

J. Beijnen, H. Guchelaar, H. Gelderblom, 2020, Clinical pharmacology and therapeutics.

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update

J. Schellens, J. Beijnen, J. Schellens, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

R. Bernards, J. Schellens, H. Rosing, 2020, The oncologist.

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

J. Beijnen, W. W. ten Bokkel Huinink, M. Schot, 1998, Anti-cancer drugs.

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?

J. Schellens, J. Beijnen, D. Meulendijks, 2016, Cancer treatment reviews.

Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.

H. Rosing, J. Beijnen, E. Stokvis, 2004, Journal of mass spectrometry : JMS.

Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study 1

J. Schellens, H. Rosing, J. Beijnen, 2000 .

Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine.

J. Schellens, H. Rosing, J. Beijnen, 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.

J. Schellens, J. Beijnen, O. Tellingen, 2007, Biomedical chromatography : BMC.

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer

A. Harris, J. Schellens, J. Beijnen, 2008, British Journal of Cancer.

Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.

H. Rosing, J. Beijnen, A. Huitema, 2020, European journal of cancer.

In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

J. Beijnen, U. Brauns, B. Nuijen, 2000, International journal of pharmaceutics.

The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

J. Beijnen, A. Schinkel, N. Loos, 2023, Biomedicine & Pharmacotherapy.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

J. Schellens, H. Rosing, J. Beijnen, 2018, Biomedical chromatography : BMC.

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma

J. Schellens, H. Rosing, J. Beijnen, 2017, Therapeutic drug monitoring.

Fast and Adequate Liquid Chromatography–Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring

J. Schellens, H. Rosing, J. Beijnen, 2017, Therapeutic drug monitoring.

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry

J. Schellens, H. Rosing, J. Beijnen, 2016, Therapeutic drug monitoring.

Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

S. Rodenhuis, J. Beijnen, A. Huitema, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

J. Beijnen, J. Double, P. Loadman, 2006, The Journal of urology.

Simultaneous Quantitative Analysis of EO9 (Apaziquone) and its Conversion Products EO5a and EO9-Cl in Human and Dog Urine by High-Performance Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry

J. Schellens, H. Rosing, J. Beijnen, 2009 .

Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.

J. Schellens, H. Rosing, J. Beijnen, 2007, Journal of pharmaceutical and biomedical analysis.

Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2006, Journal of mass spectrometry : JMS.

Phase I Study of Afatinib and Selumetinib in Patients with KRASâ•’Mutated Colorectal, Nonâ•’Small Cell Lung, and Pancreatic Cancer

R. Bernards, H. Rosing, J. Beijnen, 2021 .

MOLECULAR CANCER THERAPEUTICS | CANCER BIOLOGYAND TRANSLATIONAL STUDIES ABCB1andABCG2RestrictBrain andTestisAccumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

J. Beijnen, O. van Tellingen, A. Schinkel, 2021 .

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

J. Beijnen, A. Schinkel, R. Sparidans, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

C. Punt, J. Schellens, J. Beijnen, 2011, Clinical Cancer Research.

Degradation of suramin in aqueous solutions

J. Beijnen, A. Bult, J. J. K. D. Bosch, 1997 .

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

D. Richel, J. Schellens, J. Beijnen, 2011, Investigational New Drugs.

P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).

J. Beijnen, A. Schinkel, R. Sparidans, 2019, International journal of pharmaceutics.

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, A. Schinkel, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole.

K. Rinehart, J. Beijnen, O. van Tellingen, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection.

J. Beijnen, J. Jimeno, R. Sparidans, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin

J. Schellens, H. Rosing, J. Beijnen, 2018, Cancer Chemotherapy and Pharmacology.

Liquid chromatography‐tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of Pharmaceutical and Biomedical Analysis.

Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry.

A. Heck, J. Schellens, J. Beijnen, 2005, Journal of Mass Spectrometry.

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

J. Schellens, J. Beijnen, C. Nijenhuis, 2016, Drug metabolism reviews.

Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry

J. Beijnen, A. Schinkel, R. Sparidans, 2022, Biomedical chromatography : BMC.

Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole.

J. Schellens, J. Beijnen, J. Jimeno, 2004, Biomedical chromatography : BMC.

Increased risk of severe fluoropyrimidine‐associated toxicity in patients carrying a G to C substitution in the first 28‐bp tandem repeat of the thymidylate synthase 2R allele

J. Schellens, J. Beijnen, D. Pluim, 2016, International journal of cancer.

ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.

J. Beijnen, A. Schinkel, R. Sparidans, 2022, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability

J. Beijnen, A. Schinkel, R. Sparidans, 2021, Pharmaceutics.

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib

J. Beijnen, A. Schinkel, R. Sparidans, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of pharmaceutical and biomedical analysis.

Assay performance and stability of uracil and dihydrouracil in clinical practice

H. Rosing, J. Beijnen, A. Cats, 2023, Cancer Chemotherapy and Pharmacology.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases

J. Schellens, H. Rosing, J. Beijnen, 2018, European Journal of Clinical Pharmacology.

Commentary: Substandard medicines are the priority for neglected tropical diseases

J. Beijnen, M. Boelaert, T. Dorlo, 2012, BMJ : British Medical Journal.

Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.

F. Cavalli, J. Wanders, J. Beijnen, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

J. Schellens, J. Beijnen, A. Zandvliet, 2012, The AAPS Journal.

Ethnic differences in cardiometabolic risk profile in an overweight/obese paediatric cohort in the Netherlands: a cross-sectional study

J. Beijnen, M. Diamant, R. K. Schindhelm, 2009, Cardiovascular diabetology.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome

J. Schellens, J. Beijnen, C. Blank, 2013, European Journal of Clinical Pharmacology.

Photophobia in a Patient with High Indinavir Plasma Concentrations

J. Beijnen, A. Huitema, J. Mulder, 2003, Therapeutic Drug Monitoring.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

J. Beijnen, R. Mathijssen, A. Huitema, 2019, European Journal of Clinical Pharmacology.

Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma)

J. Schellens, J. Beijnen, M. Swart, 2000, Cancer Chemotherapy and Pharmacology.

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

H. Rosing, J. Beijnen, J. Schellens, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of oral paclitaxel.

J. Schellens, H. Rosing, J. Beijnen, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.

S. Rodenhuis, O. Dalesio, J. Beijnen, 1997, Seminars in oncology.

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

H. Rosing, J. Beijnen, A. Sparreboom, 1995, Journal of chromatography. B, Biomedical applications.

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Mats O. Karlsson, Jos H. Beijnen, Ron J. Keizer, 2010, Journal of Pharmacokinetics and Pharmacodynamics.

Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure

Willem Boogerd, Jos H. Beijnen, J. Schellens, 2001, Cancer Chemotherapy and Pharmacology.

Synthesis, radiolabelling and stability of radioiodinated m-iodobenzylguanidine, a review.

A. Wafelman, J. Beijnen, C. Hoefnagel, 1994, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

A comparison of the radiochemical stability of different iodine-131 labelled metaiodobenzylguanidine formulations for therapeutic use

A. Wafelman, J. Beijnen, C. Hoefnagel, 1994 .

Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use.

A. Wafelman, J. Beijnen, C. Hoefnagel, 1993, Nuclear medicine communications.

Chromatographic determination of the radiochemical purity of [131I]MIBG infusion fluids: a comparison and discussion of the chromatographic characteristics using three different techniques

A. Wafelman, J. Beijnen, C. Hoefnagel, 1993 .

Crizotinib-induced fatal fulminant liver failure.

J. Schellens, J. Beijnen, A. Huitema, 2016, Lung cancer.

Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium.

H. Rosing, J. Beijnen, A. Schinkel, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.

H. Rosing, J. Beijnen, A. Schinkel, 2020, International journal of pharmaceutics.

Therapeutic Drug Monitoring of Antiretroviral Drugs at Home Using Dried Blood Spots: A Proof-Of-Concept Study

J. Beijnen, A. Huitema, R. ter Heine, 2013, Antiviral Therapy.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

J. Schellens, H. Rosing, J. Beijnen, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.

H. Rosing, J. Beijnen, A. Huitema, 2012, The Journal of antimicrobial chemotherapy.

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination

J. Schellens, J. Beijnen, D. Pluim, 2013, Analytical and Bioanalytical Chemistry.

Ultra‐sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine in human plasma for a microdose clinical trial

J. H. Beijnen, J. Schellens, H. Rosing, 2018, Journal of pharmaceutical and biomedical analysis.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

Jos H. Beijnen, J. Schellens, H. Rosing, 2016, Cancer Chemotherapy and Pharmacology.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity

U. Amstutz, J. Schellens, J. Beijnen, 2016, International journal of cancer.

Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility

M. D. Harvey, J. Beijnen, B. Nuijen, 2005, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.

J. Beijnen, J. Jimeno, B. Nuijen, 2001, PDA journal of pharmaceutical science and technology.

Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.

M. D. Harvey, J. Beijnen, M. Hillebrand, 2005, Journal of pharmaceutical and biomedical analysis.

Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility

J. Beijnen, C. Lutz, B. Nuijen, 2005, Anti-Cancer Drugs.

Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its hemolytic potential

J. Beijnen, G. Sava, B. Nuijen, 2004 .

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

J. Schellens, J. Beijnen, C. Zwaan, 2017, European journal of cancer.

A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

J. Beijnen, A. Huitema, T. Dorlo, 2023, EJNMMI Research.

Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography.

J. Beijnen, M. J. van Maanen, K. D. Smits, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine.

A. Heck, J. Beijnen, J. M. Damen, 2000, International journal of pharmaceutics.

Liquid chromatographic-mass spectrometric determination of the novel, recently identified thioTEPA metabolite, thioTEPA-mercapturate, in urine.

J. Beijnen, M. J. van Maanen, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Degradation study of thiotepa in aqueous solutions.

J. Beijnen, J. M. Damen, A. Brandt, 1999, International journal of pharmaceutics.

Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.

S. Rodenhuis, J. Beijnen, A. Huitema, 1998, Journal of chromatography. B, Biomedical sciences and applications.

The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers

J. Schellens, J. Beijnen, A. Goey, 2013, European Journal of Clinical Pharmacology.

Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.

J. Beijnen, H. Boot, B. Taal, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Degradation kinetics of the investigational antitumor compound LL-D49194α1 in the presence of buffers

J. Beijnen, A. Bult, O. Bekers, 1994 .

Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.

R. Bernards, J. Schellens, H. Rosing, 2020 .

Drug Formulations: How these Affects Anticancer Drug

J. Schellens, J. Beijnen, B. Nuijen, 2014 .

High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine.

H. Rosing, J. Beijnen, H. Pinedo, 1995, Journal of chromatography. B, Biomedical applications.

A flexed posture in elderly patients is associated with impairments in postural control during walking.

W. Lems, C. Lamoth, J. Beijnen, 2014, Gait & posture.

Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine.

H. Keizer, J. Beijnen, A. Bult, 1997, Journal of Chromatography B: Biomedical Sciences and Applications.

Determination of Ifosfamide, 2- and 3-Dechloroethyifosfamide Using Gas Chromatography With Nitrogen-Phosphorus or Mass Spectrometry Detection

J. Beijnen, A. Huitema, J. V. van Putten, 2000, Therapeutic drug monitoring.

Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.

H. Keizer, J. Beijnen, A. Bult, 1996, Anticancer research.

Effect of cyclodextrin complexation on the chemical stability of doxorubicin and daunorubicin in aqueous solutions

J. Beijnen, M. Otagiri, A. Bult, 1991 .

Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

H. Rosing, J. Beijnen, A. Huitema, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP)

J. Beijnen, F. Amant, A. Huitema, 2021, Clinical Pharmacokinetics.

An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.

J. Beijnen, A. Huitema, A. Schinkel, 2011, Journal of pharmaceutical sciences.

P12 SELDI-TOF MS serum protein profiling predicts poor prognosis renal cancer patients

J. Schellens, J. Beijnen, E. Voest, 2007 .

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 2001, Anti-cancer drugs.

Incidence of Hematologic Toxicity in Older Adults Treated with Gemcitabine or a Gemcitabine-Containing Regimen in Routine Clinical Practice: A Multicenter Retrospective Cohort Study

J. Schellens, J. Beijnen, A. Huitema, 2014, Drugs & Aging.

Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.

J. Beijnen, A. Schinkel, R. Sparidans, 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Changes in Under-Treatment after Comprehensive Geriatric Assessment

J. Beijnen, P. Jansen, L. Tulner, 2010, Drugs & aging.

Bioanalysis of HIV protease inhibitors in samples from sanctuary sites.

J. Beijnen, A. Huitema, A. Huitema, 2005, Journal of pharmaceutical and biomedical analysis.

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

J. Schellens, J. Beijnen, A. Huitema, 2012, Pharmaceutical Research.

Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen.

J. Beijnen, R. Hoetelmans, R. Sparidans, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen

J. Schellens, H. Rosing, J. Beijnen, 2018, Breast Cancer Research and Treatment.

Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing

A. Zwinderman, J. Beijnen, H. Wouters, 2016, International journal of methods in psychiatric research.

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development.

H. Rosing, J. Beijnen, M. Altelaar, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

J. Schellens, J. Beijnen, A. Huitema, 2018, Investigational New Drugs.

A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices.

H. Rosing, J. Beijnen, H. Guchelaar, 2020, Biomedical chromatography : BMC.

Oral Bioavailability of Low Dose (20mg) ‘Home-Made’ Etoposide Capsules

A. C. Dubbelman, S. Rodenhuis, J. Beijnen, 1996 .

Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: Case report and a review of the literature

J. Beijnen, A. Huitema, M. Hillebrand, 2011, Human & experimental toxicology.

Thermal study of pazopanib hydrochloride

J. Schellens, J. Beijnen, B. Nuijen, 2017, Journal of Thermal Analysis and Calorimetry.

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy

J. Schellens, J. Beijnen, A. Huitema, 2014, BioMed research international.

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular‐signal‐regulated kinase and DNA in circulating tumor cells

J. Schellens, J. Beijnen, D. Pluim, 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids.

J. Beijnen, W. Underberg, R. van Gijn, 1992, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

Tandem mass spectrometry of small-molecule signal transduction inhibitors: Accurate-m/z data to adapt structure proposals of product ions.

H. Rosing, J. Beijnen, W. Niessen, 2020, Journal of Pharmaceutical and Biomedical Analysis.

Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.

J. Schellens, J. Beijnen, A. Schinkel, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The Association of Medication-Use and Frailty-Related Factors with Gait Performance in Older Patients

C. Lamoth, J. Beijnen, O. J. de Vries, 2016, PloS one.

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens

J. Beijnen, A. Huitema, T. Dorlo, 2022, Clinical and translational science.

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.

A Heerschap, A. Heerschap, J. Beijnen, 2006, European journal of cancer.

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

J. Beijnen, J. Schellens, D. Pluim, 1999, Analytical biochemistry.

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.

J. Beijnen, M. V. van Vugt, A. Huitema, 2023, Gynecologic oncology.

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)

J. Beijnen, A. Schinkel, R. Sparidans, 2021, Pharmaceuticals.

HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier.

J. Beijnen, C. Boucher, P. Portegies, 1997, Antiviral Therapy.

The in‐vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity

J. Schellens, J. Beijnen, A. Goey, 2014, The Journal of pharmacy and pharmacology.

Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen

S. Linn, J. Schellens, H. Rosing, 2014, Breast Cancer Research and Treatment.

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

J. Schellens, J. Beijnen, A. Zandvliet, 2012, The AAPS Journal.

Drug-Drug Interactions in a Geriatric Outpatient Cohort

J. Beijnen, L. Tulner, S. V. Frankfort, 2008, Drugs & aging.

Redispensing of expensive oral anticancer medicines: A practical application.

J. Beijnen, A. Huitema, B. Nuijen, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice

P. V. van Diest, H. Rosing, J. Beijnen, 2017, Oncotarget.

940 Phase I and pharmacokinetic study of topotecan (T) in combination with oral etoposide (E)

S. Rodenhuis, J. Beijnen, J. Schornagel, 1995 .

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study.

H. Rosing, J. Beijnen, M. Tibben, 2019, Journal of pharmaceutical and biomedical analysis.

Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors

J. Schellens, J. Beijnen, A. Huitema, 2020, Clinical Pharmacokinetics.

ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation

J. Beijnen, M. Valk, A. Schinkel, 2019, Archives of Toxicology.

High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.

J. Beijnen, O. van Tellingen, W. Nooijen, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties

J. Beijnen, A. Bult, W. Underberg, 2005, Pharmaceutisch Weekblad.

Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC).

J. Schellens, J. Beijnen, D. Rodenstein, 2005 .

Intoxication with Trazodone Caused by Dirty Facsimile Machine

Jos H Beijnen, J. Beijnen, Linda R Tulner, 2009, Journal of the American Geriatrics Society.

[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].

J. Beijnen, A. Witkamp, H. Boot, 1999, Nederlands tijdschrift voor geneeskunde.

924 Pharmacology of paclitaxel (P) and metabolites in patients with altered liver function

A. Graeff, H. Rosing, J. Beijnen, 1995 .

Limited Sampling Strategies for the Estimation of the Systemic Exposure to the HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Nevirapine

J. Beijnen, J. Mulder, R. Hoetelmans, 2001, Therapeutic drug monitoring.

Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice

J. Beijnen, O. van Tellingen, A. Bult, 2004, Investigational New Drugs.

Severe encephalopathy and polyneuropathy induced by dichloroacetate

J. Beijnen, W. Boogerd, D. Brandsma, 2010, Journal of Neurology.

Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab.

J. Baars, C. Damen, J. Beijnen, 2011, Journal of pharmaceutical and biomedical analysis.

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

A. Baruchel, J. Beijnen, C. Zwaan, 2019, Clinical Pharmacokinetics.

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.

J. Beijnen, A. Huitema, E. V. van Gorp, 2005, British journal of clinical pharmacology.

HAART, or just mini-HAART?

J. Beijnen, J. Mulder, P. Meenhorst, 2001, Journal of acquired immune deficiency syndromes.

A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry

H. Rosing, J. Beijnen, A. Huitema, 2010, Clinical chemistry and laboratory medicine.

Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.

J. Schellens, J. Beijnen, A. Huitema, 2006, Biomedical chromatography : BMC.

Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, R. Hoetelmans, R. Sparidans, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Radiochemical Purity, at Expiry, and Radiochemical Stability of Iodine-131 Labelled Meta-iodobenzylguanidine Concentrates for Intravenous Infusion

A. Wafelman, J. Beijnen, C. Hoefnagel, 1996, Nuklearmedizin.

Pharmacokinetics of sunitinib in an obese patient with a GIST.

J. Beijnen, D. Burger, I. Desar, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Bcrp1;Mdr1a/b;Mrp2 Combination Knockout Mice: Altered Disposition of the Dietary Carcinogen PhIP (2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine) and Its Genotoxic Metabolites

Tom F. A. de Greef, Jos H. Beijnen, Luc Brunsveld, 2014, Molecular Pharmacology.

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

J. Schellens, J. Beijnen, E. Voest, 2007, Investigational New Drugs.

Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2004, Rapid Communications in Mass Spectrometry.

Chemical stability of cyclophosphamide, trofosfamide, and 2- and 3-dechloroethylifosfamide in aqueous solutions

J. Beijnen, T. Aalbers, W. Underberg, 1996 .

Effect of Heat Treatment of Potentially Infected Blood Samples on Therapeutic Drug Monitoring of Selected Drugs

J. Beijnen, D. Burger, R. van Gijn, 1993, The Annals of pharmacotherapy.

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors

J. Beijnen, T. Dorlo, J. Hendrikx, 2021, EJNMMI Research.

Capillary zone electrophoresis–mass spectrometry as a tool in the stability research of the luteinising hormone-releasing hormone analogue goserelin

J. Beijnen, A. Bult, J. J. K. D. Bosch, 1997 .

Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.

J. Schellens, J. Beijnen, U. Jaehde, 2012, Clinical pharmacokinetics.

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment

J. Schellens, J. Beijnen, A. Huitema, 2016, European Journal of Clinical Pharmacology.

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

J. Schellens, H. Rosing, J. Beijnen, 2018, Pharmaceutical Research.

Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer.

J. Schellens, J. Beijnen, W. Meinhardt, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract LB-49: ABC transporters in the blood-brain barrier limit the brain penetration of the PARP inhibitor ABT-888

J. Beijnen, J. Beumer, S. Christner, 2010 .

Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.

J. Beijnen, A. Huitema, E. V. van Gorp, 2011, Bioanalysis.

SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity.

Marie-Christine W. Gast, E. Rutgers, J. Schellens, 2006, Cancer biomarkers : section A of Disease markers.

Degradation kinetics of vincristine sulphate and vindesine sulphate in aqueous solutions

J. Beijnen, O. V. D. Houwen, D. Vendrig, 1989 .

Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids.

J. Beijnen, W. Underberg, D. Vendrig, 1989, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

Stability of intravenous admixtures of doxorubicin and vincristine.

H. Rosing, J. Beijnen, O. Meuwissen, 1986, American journal of hospital pharmacy.

Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples.

J. Schellens, J. Beijnen, R. Sparidans, 2010, Rapid communications in mass spectrometry : RCM.

Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.

C. Damen, J. Schellens, H. Rosing, 2008, Journal of pharmaceutical and biomedical analysis.

Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer.

J. Schellens, J. Beijnen, E. Voest, 2006, Journal of Clinical Oncology.

Therapeutic drug monitoring of non-anticancer drugs in cancer patients.

J. Schellens, J. Beijnen, M. Joerger, 2004, Methods and findings in experimental and clinical pharmacology.

Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.

H. Rosing, J. Beijnen, E. Voest, 2010, Neoplasia.

Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.

D. Jong, J. Schellens, J. Beijnen, 2015 .

Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates.

J. Beijnen, A. Schinkel, R. Sparidans, 2021, Journal of pharmaceutical and biomedical analysis.

Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS.

H. Rosing, J. Beijnen, M. Tibben, 2021, Journal of Pharmaceutical and Biomedical Analysis.

Ultrasensitive Bioanalytical Assays for Cytotoxic Drugs: Focus on Locally Administered Anti-Cancer Agents

J. Schellens, H. Rosing, J. Beijnen, 2008 .

Phase I and pharmacokinetic study of ecteinascldin-743 (ET-743) given as a one hour infusion every 21 days

J. Beijnen, J. Smyth, C. Twelves, 1997 .

Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry.

A. C. Dubbelman, J. Schellens, H. Rosing, 2013, Rapid communications in mass spectrometry : RCM.

Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report.

D. de Jong, J. Wanders, J. Schellens, 2011, Tumori.

Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review).

J. Beijnen, P. Knoester, W. Underberg, 1993, Anticancer research.

Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification.

J. Beijnen, R. Sparidans, V. J. Somovilla, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Stability study of concentrate-solvent mixture & infusion solutions of Jevtana® cabazitaxel for extended multi-dosing

J. Beijnen, A. Huitema, B. Nuijen, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice

J. Beijnen, M. Hillebrand, A. Schinkel, 2023, Pharmaceutical Research.

Growth factors in human ovarian cancer.

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1997, Cancer treatment reviews.

Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates.

J. Schellens, J. Beijnen, A. Schinkel, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

T. Schumacher, G. Kenter, J. Beijnen, 2021 .

Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling

J. Beijnen, A. Huitema, T. Dorlo, 2023, EJNMMI Physics.

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

C. Punt, J. Schellens, J. Beijnen, 2011, Clinical Cancer Research.

Gait dynamics to optimize fall risk assessment in geriatric patients admitted to an outpatient diagnostic clinic

T. Hortobágyi, N. Vuillerme, C. Lamoth, 2017, PloS one.

Stability of famotidine in commonly used nutritional infusion fluids.

J. Beijnen, J. Koomen, W. Underberg, 1988, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

H. Rosing, J. Beijnen, M. Hillebrand, 2005, Rapid communications in mass spectrometry : RCM.

Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs.

J. Schellens, J. Beijnen, J. D. de Vos, 2015, Veterinary and comparative oncology.

The performance of model-based versus rule-based phase I clinical trials in oncology

J. Schellens, J. Beijnen, A. Huitema, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling

Marie-Christine W. Gast, Jos H Beijnen, Marie-Christine W Gast, 2008, BMC Medical Genomics.

Buparlisib is a brain penetrable pan-PI3K inhibitor

J. Beijnen, M. D. de Gooijer, O. van Tellingen, 2018, Scientific Reports.

Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS.

Marie-Christine W. Gast, E. Rutgers, J. Schellens, 2009, Oncology reports.

Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma.

H. Keizer, J. Beijnen, A. Bult, 1993, Journal of chromatography.

Characterization of Absorption, Metabolism, and Elimination of Niraparib, an Investigational Poly (ADP-Ribose) Polymerase Inhibitor, in Cancer Patients

J. Schellens, H. Rosing, J. Beijnen, 2017 .

Preparation and stability testing of a hydrogel for topical analgesia

J. Beijnen, C. Koks, Y. L. Nortier, 1995, Pharmacy World and Science.

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs

J. Beijnen, F. Amant, T. Dorlo, 2023, Clinical Pharmacokinetics.

Novel applications of growth factors in solid tumors

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1999 .

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women

P. V. van Diest, H. Horlings, W. Zwart, 2021, NPJ breast cancer.

Evaluation of Pharmacotherapy in Geriatric Patients after Performing Complete Geriatric Assessment at a Diagnostic Day Clinic

J. Beijnen, L. Tulner, S. V. Frankfort, 2006, Clinical drug investigation.

Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.

J. Beijnen, J. Borleffs, R. Hoetelmans, 2002, British Journal of Clinical Pharmacology.

Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Anti-cancer drugs.

A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO‐101 in Patients With Advanced Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of clinical pharmacology.

Quantitative LC-MS/MS analysis of 5-hydroxymethyl-2'-deoxyuridine to monitor the biological activity of J-binding protein.

H. Rosing, J. Beijnen, A. Perrakis, 2020, Analytical biochemistry.

Development, validation, and clinical application of a high‐performance liquid chromatography‐tandem mass spectrometry assay for the quantification of total intracellular &bgr;‐decitabine nucleotides and genomic DNA incorporated &bgr;‐decitabine and 5‐methyl‐2′‐deoxycytidine

J. Schellens, H. Rosing, J. Beijnen, 2019, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

J. Beijnen, A. Schinkel, R. Sparidans, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Contraindications for anticoagulation in older patients with atrial fibrillation; a narrative review.

J. Beijnen, V. Kwa, L. Tulner, 2010, Current Drug Safety.

Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2014, Journal of pharmaceutical and biomedical analysis.

Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.

J. Beijnen, O. van Tellingen, E. Kemper, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)

J. Beijnen, M. Rutgers, A. Kuin, 1999, British Journal of Cancer.

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

J. Wanders, E. Raymond, J. Beijnen, 2002, British journal of clinical pharmacology.

Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.

J. Schellens, J. Beijnen, O. van Tellingen, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Population pharmacokinetics of the novel anticancer agent KRN7000

G. Giaccone, C. Punt, J. Schellens, 2002, Cancer Chemotherapy and Pharmacology.

Morphine Induces Hyperalgesia without Involvement of µ-Opioid Receptor or Morphine-3-glucuronide

A. Dahan, J. Beijnen, Amanda R. Waxman, 2012, Molecular medicine.

Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

J. Schellens, J. Beijnen, A. Huitema, 2010, Clinical pharmacokinetics.

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

J. Schellens, J. Beijnen, A. Huitema, 2014, Therapeutic drug monitoring.

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

J. Beijnen, J. Mulder, R. Hoetelmans, 1997, Pharmacy World and Science.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Pharmacogenetics and genomics.

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies

A. Berns, J. Beijnen, W. Leenders, 2010, Clinical Cancer Research.

New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

J. Schellens, J. Beijnen, D. Pluim, 2008, Molecular Cancer Therapeutics.

Concise drug review: azacitidine and decitabine.

J. Schellens, J. Beijnen, Ellen J B Derissen, 2013, The oncologist.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases

J. Schellens, H. Rosing, J. Beijnen, 2018, European Journal of Clinical Pharmacology.

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy

S. Rodenhuis, O. Dalesio, J. Beijnen, 2002, Bone Marrow Transplantation.

Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting

L. Lagae, J. Beijnen, F. Amant, 2009, International Journal of Gynecologic Cancer.

Universal access to quality medicines: prioritisation of a-priori solutions.

Raffaella Ravinetto, Thomas P C Dorlo, Marleen Boelaert, 2012, The Lancet. Infectious diseases.

Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients

J. Beijnen, P. D. de Vries, A. Huitema, 2008, Antimicrobial Agents and Chemotherapy.

Clinical experience with aurora kinase inhibitors: a review.

J. Schellens, J. Beijnen, D. Boss, 2009, The oncologist.

Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.

J. Schellens, H. Rosing, J. Beijnen, 2015, Journal of pharmaceutical and biomedical analysis.

Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model.

J. Beijnen, R. Devlieger, F. Amant, 2010, Gynecologic oncology.

Concise drug review: pazopanib and axitinib.

J. Schellens, J. Beijnen, R. van Geel, 2012, The oncologist.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Abstract 5537: GSH-conjugation improves efficacy of Doxil against intracranial xenografts

J. Beijnen, W. Boogerd, R. Dorland, 2010 .

Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.

J. Beijnen, A. Schinkel, R. Sparidans, 2023, Biomedical chromatography : BMC.

Development of farnesyl transferase inhibitors: a review.

J. Schellens, J. Beijnen, N. Appels, 2005, The oncologist.

Application of PET/CT in the development of novel anticancer drugs.

J. Schellens, J. Beijnen, D. Boss, 2008, The oncologist.

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

J. Schellens, J. Beijnen, H. Boot, 2013, International journal of radiation oncology, biology, physics.

‘Flooding’ of the lungs and severe dyspnea in a patient with bronchoalveolar carcinoma

J. Beijnen, R. Keizer, P. Baas, 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab

J. Baars, J. Beijnen, A. Huitema, 2011 .

C linical harmacology Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva ® ) and Gefitinib (Iressa ® )

J. Beijnen, W. S. Siegel-Lakhai, J. H. M. Schellensa, 2005 .

Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer.

J. Schellens, J. Beijnen, I. Meijerman, 2008, Cancer treatment reviews.

DNA vaccination in oncology: current status, opportunities and perspectives.

J. Beijnen, J. Haanen, K. Oosterhuis, 2010, Current clinical pharmacology.

The absolute quantification of eight inter‐α‐trypsin inhibitor heavy chain 4 (ITIH4)‐derived peptides in serum from breast cancer patients

Marie-Christine W. Gast, J. Schellens, J. Beijnen, 2010, Proteomics. Clinical applications.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity

U. Amstutz, J. Schellens, J. Beijnen, 2016, International journal of cancer.